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The goal of my research has been to investigate the mechanisms by which inorganic 
polyphosphate (polyP) is degraded in vivo.  PolyP is a linear chain of phosphate moieties linked 
through high-energy phosphoanhydride bonds and can range in size from three-phosphates-
long to thousands.  Naturally, these molecular chains are stored in cells within organelles called 
acidocalcisomes—metal-filled acidic cellular compartments.  Human platelets, for example, 
store polyP of 60-100mer in dense granules (a type of acidocalcisome); upon activation, 
platelets release the procoagulant molecule into blood.  Once in blood, polyP presumably 
decays.  Previous studies indicated that polyP incubated in human serum has a half-life of about 
90 minutes.  Our hypothesis, therefore, was that native serum endo- and exopolyphosphatases 
degraded polyP.   
 
To study the degradation of polyP in vivo and identify putative polyphosphatases, we needed to 
develop a high-throughput method for measuring polyphosphatase activity.  The study of polyP 
long has been hampered by the paucity of high-throughput methods for detecting and 
quantifying rates of polyphosphate degradation.  Adapting carboxylic acid chemistry to esterify 
polyP’s terminal phosphates with alcohols, we created chromogenic and fluorogenic 
polyphosphatase substrates that allow one to measure real-time activity of either endo- or 
exopolyphosphatases, depending upon assay configuration.  We confirmed the products’ 
identities through 1D and 2D 31P, 1H, and 13C NMR analyses.  In proof-of-principle experiments 
we showed that the substrates were useful for spectrophotometrically monitoring the activities 
of commercially-available polyphosphatases in real time.  Utilizing these substrates, we 
identified a new function for the clinically significant enzyme, Nudt2.  The chemistry and 
substrates developed would be not only applicable for synthetic and clinical applications, but 
also for identifying putative human sera polyphosphatases. 
 
In attempting to identify the putative sera polyphosphatases, we found that the majority of 
polyphosphate degradation in serum was metal-mediated, rather than enzyme-mediated.  
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Using a 96-well plate format assay, we tested a variety of conditions.  PolyP degradation in 
serum had the following characteristics: resistance to canonical phosphatase inhibitors, 
resistance to heat, a calcium dependency, and a pH dependency.  Our results show that at 
physiological pH (7.4) and above, calcium concentrations near and above those in serum (x ≥ 
1.25 mM) can hydrolyze polyphosphate chains.   
 
Most unicellular organisms and many human cells (e.g. mast cells, platelets) store polyP with 
divalent metals in acidocalcisomes, and the dissolution of acidocalcisome polyP in response to 
alkaline stress occurs in various organisms and in situ marine mineral sedimentation.  Until 
now, the reigning hypothesis has been that this polyphosphate degradation is enzyme-
catalyzed.  Our findings raise a question, though, as to whether or not calcium ions alone may 
be sufficient to facilitate polyP degradation during times of cellular alkaline stress.  If so, then 
the acidification of acidocalcisomes may be an evolutionary cellular adaption that prevents 
calcium-mediated polyphosphate degradation during times of non-stress and additional work 
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CHAPTER 1: INTRODUCTION  
1.1 Blood Clotting: Global Picture of Health   
By numbers, the most proficient killers in the world today are ischemic heart disease (heart 
attack) and stroke, accounting for three-out-of-ten deaths.1  The root cause of these diseases is 
a pathological process called thrombosis, or the formation of unwanted blood clots within 
arteries or veins.  Blockage of veins and arteries by clots prevents blood flow to tissues, 
resulting in a lack of oxygen supply to tissues, or ischemia.  If such a block occurs in cardiac 
tissue or the brain, the result would be a heart attack or stroke, respectively.  Thrombosis 
occurs when the body has lost the ability to maintain hemostasis, or the ability to clot blood 
only when trying to stop blood loss.  Thrombogenicity often is correlated with poor diet, 
infection, senescence, sepsis, cancer, or other causes.  Preserving a balance is delicate, if not 
sometimes precarious, and is a major focus in healthcare. We need our blood to exist in a liquid 
state in order to bathe our tissues with nutrients and oxygen, but we also need part of it to 
solidify instantly at the site of an injury or infection to prevent further blood loss or pathogenic 
invasion.  Balancing liquid and solid blood requires the concerted action of proteins, cells, 
vasculature, and signals; and any number of factors can tip the balance towards a 
prothrombotic or hemorrhagic state.   
 
The American Heart Association expects the costs of cardiovascular disease in the US to rise 
more than $800 billion by 2030.2  With a rise in atherosclerosis, a recurring quandary for 
healthcare providers is how to prevent thrombosis in at-risk patients while not predisposing the 
patients to hemorrhage, or uncontrolled bleeding.  A patient given anti-platelet (aspirin, etc.) or 
anticoagulant (warfarin, etc.) drugs to prevent thrombosis, for example, might be unable to 
stop bleeding in a car accident.  Additionally, science and medicine, so far, have yet to find or 
synthesize antithrombotics that lack side effects.  Research continues, therefore, for new ways 
to nudge hemostasis in one direction or another without pushing patients towards 
coagulopathies.  Some recent developments, especially in the contact pathway of blood clotting 




Much of the research in our lab recently has focused on studying a molecule released from 
platelets called polyphosphate (polyP).  PolyP is a procoagulant molecule that is able to 
modulate blood clotting and immunity.  Understanding how this molecule is regulated in 
humans, therefore, may provide insights for the exploration and utility of novel inhibitors for 
the polyP.  My research in the Morrissey Lab is focused on the mechanisms of polyP 
degradation in humans.  In this work I will describe polyP and its known effects in detail.   
1.2   Polyphosphate (PolyP): Structure and Sources 
1.2.1:       STRUCTURE & PROPERTIES 
PolyPs are linear polymers of orthophosphates joined together through high-energy 
phosphoanhydride bonds, and these chains can range in length from tens to thousands of 
phosphates long [Figure 1.1]. The pKa of the internal phosphates is ~ 3.0 while the terminal 
phosphates’ is ~ 7.5, so at physiological pH, polyP is a weak buffer and highly electronegative.  
As such, polyP is a known chelator.  In fact, whether in nature (in cells) or industrially 
synthesized, polyP is found comingled with metal counterions.  Both acid – and base—catalysed 
hydrolysis, especially at high temperatures (T  40 oC), cause fairly rapid hydrolysis of polyP 
from the terminal end phosphates.  Center hydrolysis is also known to occur and results in 
metaphosphate formation through what is thought to be almost a looping mechanism.  The 
ends of polyP are the most reactive phosphates in the chain, and it is known that the ends can 
join together, forming loops, though these loops are transient structures.  Branched polyPs are 
also sometimes created, but their formation seems transient, too, with the exceptions of 
trimeta and hexameta phosphate, which are stable under physiological conditions [Figure 1.1].  
The linear form of polyP is fairly stable and biodegradable, making polyP both an attractive 
polymer for industrial applications and an important biomolecule.  
1.2.2:       IN INDUSTRY 
PolyP is also an industrial chemical with applications in areas such as water treatment, food 
processing, fertilizers and flame retardants.  In industrial settings polyP is synthesized from 
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melts which include combining sodium, calcium, and/or potassium and phosphate(s) in large 
ovens, heating the melts to over 1000 oC.  Fibers formed this way have a variety of names 
(Maddrell’s, Kurrol’s, etc. salts) depending on the phosphate fibers’ composition, and changing 
the Ca:P ratio can change the overall fiber structure, length, and tensile properties.  In the 
1980’s scientists working at the Monsanto Company (St. Louis, MO) looked to polyP as an 
alternative to asbestos, but eventually nixed the project.3  Today, polyP is used in a number 
applications such as in food preservatives (retains water), toothpaste, smokeless cigarettes, etc.  
Some of this polyP is available commercially and is some of the material that we use in 
experiments.   
1.2.3:       IN MICROBES: ACIDOCALCISOMES 
Long before humans were fabricating phosphate fibers in kilns with high heat, microbes were 
synthesizing polyP from ATP.  PolyP is, in fact, widespread throughout biology and implicated in 
a multitude of physiologic processes.  In bacteria and unicellular eukaryotes, polyP is 
synthesized from ATP by polyP kinases and degraded by exo- and endo(poly)phosphatases, 
which sequentially remove terminal phosphates from polyP or hydrolyze internal 
phosphoanhydride bonds, respectively.  Though some of the enzymes responsible for degrading 
polyP have been identified in unicellular organisms, the same enzymes in higher eukaryotes 
remain relatively poorly studied, with a few notable exceptions: mammalian alkaline 
phosphatase (a highly potent exopolyphosphatase), H-Prune, and prostatic acid phosphatase, 
among others.  The orthophosphate collected and stored by microbes often finds its way into 
macromolecules, such as DNA or polyP. 
 
PolyP usually is stored in metal-filled organelles and participates in an array of physiological 
upkeep: osmotic maintenance, toxic metal sequestration, pathogenic virulence, pathogen-host 
interaction, nutritional stress response, bone generation, calcium mobilization, (possibly) 
oxidative stress relief, and many more.  All known cellular polyP storage inclusions—
acidocalcisomes, lysosomes and vacuoles, Weibel-Palade bodies—are acidic-to-neutral 
compartments, ranging in pH from 4.5-7.0.  In these ‘dense granules,’ polyP is comingled with 
various metabolites and metals, the most abundant of which is often calcium.  These stores 
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have been called a number of names: yolk platelets; metachromatic or calcareous corpuscles; 
anisotropic structures; clear, Babes-Ernst, dense, electron-dense, volutin (volutankuge)4, or 
azurophilic granules (because they take up the blue dye).  Docampo and Moreno have given all 
of these structures the name “acidocalcisome” as a way of describing two of their general 
features.   Acidocalcisomes in microbes range in size from 15 to 200 nm5 in diameter and have 
been known to contain the following, though, in different amounts: basic amino acids, 
polyphosphate, pyrophosphate, divalent metals, and phosphatases.  The polyP stored within 
acidocalcisomes is non-static.  Microbes experiencing alkaline stress, for example, will hydrolyze 
stored polyP to acidic orthophosphates, lowering cellular pH to tolerable levels.  Recently, it has 
been discovered that like microbes, human mitochondria, osteoclasts, melanocytes, 
macrophages, and platelets also house dynamic stores of polyP. 
1.2.4:       IN PLATELETS 
In 2004 Ruiz et al. observed something strange about platelets: their dense granules are 
strikingly similar to the acidocalcisomes found inside pathogenic trypanosomes.6  Platelets, or 
thrombocytes, are the blood cells most responsible for propagating blood clotting.  When 
platelets sense vascular damage, they attach to the site of injury and begin to pile onto one 
another, forming a plug for the aperture.  Platelets at the site are activated, and as a result, 
they change shape and unload their granular contents into circulation.  Platelet dense granules 
(also called -granules) contain ADP, which activates other platelets7; diadenosine 
polyphosphates (ApnAs),
8 which effects vasodilation among other actions; serotonin, which 
causes vasoconstriction7 at the injury site; pyrophosphate (PPi); potassium; and divalent metals 
(calcium, zinc9, 10), which facilitate clotting-cascade-protein-to-membrane binding.  These 
excreted signaling molecules help accelerate the clotting process upon release from -granules.   
 
Ruiz et al. also found that, like the acidocalcisomes of trypanosomes, human platelets, too, 
contained polyP.  Unlike microbial polyP, which can reach thousands of orthophosphates long, 
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platelet polyP was 60-100 phosphates in length.  They estimated that there would be ~130 mMa 
of polyP within a dense granule11-13 and that this polyP was complexed with calcium in 
approximately a 1:1.76 (polyP:Ca) ratio.b  The Docampo lab were unsure whether or not all the 
polyP was released upon platelet activation, but hypothesized that polyP might contribute to 
hemostasis.  They walked across campus to discuss the possibility of furthering the 
investigation together with the Morrissey lab.   
 
PolyP of the size released from platelets is procoagulant in nature and likely very physiologically 
important for blood clotting.  Among other actions, binding to and modulating coagulation 
proteins is a role of polyP.  One hypothesis for polyP’s main mechanism of action is the 
possibility of polyP acting as soluble template or platform onto which multiple protein binding 
partners can dock.  Dr. S.A. Smith has posited that, considering polyP’s ubiquity and 
electronegative constitution, polyP may be nature’s water-soluble analogue of the phospholipid 
membrane.  Since 2004, the Morrissey lab and others have studied the effects of polyP in 
clotting and have determined many (possible) operations of polyP in blood clotting: 1) initiating 
clotting via the contact pathway15-17, 2) accelerating factor V generation and inhibiting Tissue 
Factor Pathway Inhibitor (TFPI)15, 16, 3) enhancing fibrin formation17-19, 4) and accelerating 
factor XI back-activation by thrombin.20  Especially pivotal are the discoveries that polyP 
accelerates (by ~3,000-fold) thrombin’s ability to proteolyse Factor XI and that polyP initiates 
                                                             
a This estimate is based upon the platelet -granule volume cited given in Holmsen & Weiss (1979).5 Holmsen & 
Weiss cite the work of Costa et al. 6 as the source of -granule specifications assumed.  Holmsen & Weiss write that 
“The calculations [of Costa et al.] are based on the assumption that the granule is spherical and has a diameter of 
198 nm…each granule is then 6.69 x 10-3µm3…”; however, 4/3(99 nm-4 nm)3 ≠ that volume. Additionally, 
Costa et al. estimated the volume of the granules both in 1) a theoretical manner and 2) an experimentally-derived 
manner. For the theoretical method, they cut granule imprints from film, compared the cutouts’ masses to the 
masses of perfect circles, and, from that information, found an average volume.  For the experimental method, the 
authors measured the observed diameters of granules and granule “cores” using microscopy, citing the Method II 
of Pletscher et al. (1969)
7
 (rabbit storage granules).  It is unclear which average parameters are used for calculating 
the final volume of the granules.  (I checked with Dr. R. Gennis to see if there might be something missing from my 
own calculation that would account for the discrepancy.)  If the granule volume were based upon a radius of 
~91 nm, then the [polyP] almost would double, from an estimate of ~145 mM to one of ~280 mM.  Platelet -
granules are known to differ in size, and, likely, the concentration of molecules changes, as platelets can absorb 
certain molecules (e.g. serotonin) from the environment; the concentration seems to be in the mM range by either 
calculation and the exact [polyP] is probably moot anyway. 
b Other counter ions that have been found in various acidocalcisomes include spermidine, serotonin, amino acids, 
other metals etc.11, 14 
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the contact pathway.  These two topics will be discussed further.  To really appreciate the 
magnitude of those findings and their clinical significance, however, one needs at least a 
superficial knowledge of how blood clotting works, especially with regards to the contact 
pathway of blood clotting.  For the sections on tissue factor and coagulation, it may be helpful 
to refer to Figure 1.2.   
1.3   Overview of Hemostasis 
We have a finite amount of blood that circulates in our bodies, so we have to have a process to 
stop blood loss quickly once we have a cut.  When vascular damage occurs, our hemostatic 
system works, first, to minimize blood loss from the area and, later, to reestablish the vascular 
network.  The system does so by sensing the damage, constricting conduits, calling immune and 
pro-coagulant cells to the area, and leveeing the breech.  Once the plug, or clot, is no longer 
needed, the body breaks down the structure and restores flow.  There are two descriptive 
divisions of blood clotting, one of platelet involvement and the other of coagulation factor 
contribution; and there are two blood clotting pathways related to these divisions: the Tissue 
Factor pathway and the Contact pathway.   
1.3.1:       PLATELET—VESSEL WALL INTERATCTIONSc 
The first directive of hemostasis involves plugging the hole immediately, and this is 
accomplished by attracting specialized cells—the platelets—to the damaged area.  Platelets are 
major players in hemostasis.  They not only propagate and accelerate the clotting, but they also 
physically pull the edges of wounds together to aid healing.  Platelets are round, discoid cells 
born from bone marrow that circulate in the blood.  They have no nuclei, yet they respond 
readily to fluctuations in shear stress; they shape change, apprise patrolling leukocytes, adhere 
to one another and the vessel wall, and release molecular messages upon activation.  
Contained within these cells are granules (α- and -) packaged with many small molecules 
important to clotting.  When platelets sense tissue damage, they “activate,” or, in other words, 
change shape, grab ahold of the frayed area, flip lipids, and exocytose granule contents.   
                                                             
c This was originally termed, “1o Hemostasis.” 
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The collagen exposure from broken blood vessels attracts and activates platelets. Release of 
small molecules from granules amplifies platelet activation.  The most numerous granules in a 
platelet are α-granules.  Contained within α-granules are chemokines, fibrinogen, p-selectin, 
and von Willebrand factor (vWf) among other contents.  These molecules are critical for 
platelet adhesion to one another and to the vessel wall, and patients with α-granule 
deficiencies have mild to moderate bleeding diathesis and mild thrombocytopenia.21   
 
-granule cargo consists mostly of small molecules, rather than large proteins.  ADP is a water-
soluble agonist that, once dispelled from the -granules of one platelet, binds to the P2Y1 and 
P2Y12 receptors of other platelets.
d  P2Y1 and P2Y12 receptors are G-coupled protein receptors 
(GPCRs), and binding of ADP to these receptors causes downstream signaling that results in 
granule content secretion from the second platelet wave and upregulation of adhesive 
integrins.22  Like ADP, diadenosine polyphosphates (ApnAs, where n = 3,4,5,6) are released from 
-granules23-25 and provoke P2-receptors.  These megakaryocyte-made metabolites are potent 
molecular effectors, requiring only micromolar concentrations to induce action, and they are 
degraded ten-times more slowly than ADP or ATP.8  The ApnAs have varying effects on platelet 
aggregation and vaso-control, depending on the length of the phosphate chain separating the 
two adenosines.26, e  Overall, the release of small molecular messengers from -granules is 
procoagulant in nature and important for hemostasis.  Metabolites like ADP and ApnAs promote 
clotting by enhancing platelet activation and adhesion and cohesion, while calcium promotes 
coagulation-factor—phospholipid binding.  Patients who have -granule storage pool 
deficiencies (-SPD) such as Hermansky-Pudlak syndrome have mild-to-moderate bleeding 
diathesis.21  Work is being conducted currently to see what role, if any, polyP has in platelet 
signaling or binding. 
 
                                                             
d
 A PY2 receptor is a purinergic G-protein-coupled receptor. 
e Platelets can be divided into subpopulations based upon the density/composition of their -granules, and these 
physical distinctions are known to translate into physiological differences.  One hypothesis for the presence of 
seemingly antagonistic molecules within the same organelle is that ApnAs of different sizes may be distributed 
unequally among different tiers of platelets. 
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In hemostasis platelets seem almost chivalrous: immunological informants,27 protein platforms, 
self-sacrificing cellular sandbags.  Sometimes, however, the overzealousness of platelets 
exacerbates inflammation and promotes thrombosis, and growing awareness of platelets’ part 
in atherosclerosis has made platelets popular drug targets.28, 29  Many of these “anti-platelet” 
drugs mitigate the effects of the small molecules released from platelets.  Clopidogrel (Plavix), 
prasugrel, and ticagrelor, for example, antagonize the P2Y12 receptor,
30 and in the late 2000s 
clopidogrel was the top-selling drug, grossing billions of dollars.31  In development now, too, are 
Ap4A mimetics for pharmacological use.  Ap4A curbs platelet aggregation in vivo
8 by inhibiting 
ADP-induced platelet activation.32  The molecule’s half-life upon release into plasma33 is 
controlled by both soluble plasma34-38 and cellular ecto-phosphatases.39-41  As a result of these 
findings, many labs are synthesizing and testing extended-half-life ApnAs in which one or more 
phosphate moieties have been exchanged substitutively.42-45   
 
Perhaps unsurprisingly, drugs purposed for crippling platelets’ abilities to propagate hemostasis 
historically have come with bleeding side effects, especially when the treatments are combined 
with aspirin (a common, over-the-counter anti-platelet drug).46  Many current anti-platelet 
compounds also produce unwanted aftereffects or have reduced efficacy when combined with 
other medications.  Extremely relevant in trauma and surgery, too, is timing; the effects of 
anticoagulants are either reversible or fade with time.  Managing the length of that time—with 
therapeutics or otherwise—can be critical, however, and each person is a multitude of 
variables.47, 48  Research continues for new ways to forestall thrombosis without simultaneously 
predisposing patients to hemorrhage.  Though polyP, like ApnAs and ADP, is released from 
platelet -granules, polyP’s inhibition as a possible therapy, so far, seems promising.49-53   
1.3.2:       COAGULATIONf & THE TISSUE FACTOR PATHWAY 
Platelets are an essential part of the hemostatic plugs that stop blood leakage; however, the 
mere presence of platelets and their -granule contents at an injury site is insufficient for 
making a stable clot.  Stabilization of the clot occurs through a series of protease reactions in 
                                                             
f This process was formerly named, “2o hemostasis.” 
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which blood is transformed from a liquid to a solid state.  Once platelets have initially adhered 
at an injury site, the body must mesh them into an occlusion.  In coagulation, proteins in the 
blood (coagulation factors) help sew proteinaceous tendrils around those platelets, 
strengthening the platelets’ connections to the extracellular matrix and to one another.   
1.3.2.1       Tissue Factor 
When we normally think of hemostasis, the way that our body prevents us from bleeding-out 
from a wound, we are thinking of the Tissue Factor Pathway (TFP) [Figure 1.2].  The pathway’s 
namesake is an important procoagulant integral membrane protein called Tissue Factorg,54-57, so 
named because it is a factor that lines the outside of tissues (such as blood vessels).58, 59  Blood 
vessels are like pipes, and the inside of a blood vessel through which blood would flow is called 
the lumen.  The lumen of a blood vessel is formed in space by a layer of tunica intima 
(endothelium, basal lamina), which is sheathed by tunica media (smooth muscle, elastic 
lamina).  These two layers are covered by adventitial tissue, which is wrought with tissue factor. 
54-57  The liquid portion of blood that flows through arteries and veins is called plasma, and 
contained within plasma are red blood cells (erythrocytes), platelets (thrombocytes), white 
blood cells (leukocytes) and many proteins, including clotting factors.  Most clotting factors are 
made by the liver.  Tissue factor, however, is synthesized by many cell types.  Exposure of tissue 
factor to clotting factors in the blood initiates the coagulation cascade. 
 
In any healthy individual the tissue factor in blood vessels is separated from the clotting factors 
by several buffer layers of tissue (as mentioned above).  When injury happens and vessels are 
cut, the tissue factor that was on the outside of the vessel wall is exposed to clotting factors in 
the plasma and clotting begins.  Most of the clotting factors require the use of cell membrane 
surfaces for proper functioning.  Activated platelets flip their phospholipids, exposing 
negatively-charged phospholipids (phosphatidylserine and phosphatidic acid60) to the 
environment.61  Lysed or distressed cells, too, will expose negatively-charged lipids.  The 
                                                             




coagulation factors, which are mostly serine proteases, use their GLA domainsh to bind 
membrane surfaces (reversibly).62, 63  A cascade of proteolytic events ensues, culminating in the 
generation of thrombin, the central enzyme in coagulation.   
 
Vitamin K antagonists (e.g. warfarin/Coumadin) are commonly-prescribed indirect 
anticoagulants and have been given for over 50 years.64  Warfarin was first used as rat poison 
when it was discovered but today is a standard prescribed antithrombotic drug.  These 
compounds work by inhibiting the posttranslational modification of GLA domains on certain 
coagulation factors (prothrombin, fVII, fIX, fX) and some inhibitory proteins of coagulation.  
Without functional GLA domains, these proteins are impaired in their abilities to bind 
membrane surfaces.  Because coagulation factor binding to membranes enhances enzymatic 
activity, any drugs that negatively affect the binding interaction will also negatively affect 
coagulation.  Patients taking warfarin must be monitored closely because too little or too much 
warfarin in the system can cause a thrombotic recurrence or serious bleeding, respectively.  
Reversing the effects of warfarin naturally takes 3-6 days,48 the amount of time needed for the  
liver to produce new, fully-functional coagulation factors.    
1.3.2.2       COAGULATION FACTORS & GENERAL COAGULATION MECHANISM 
Clotting factors’ names are represented by f, for “factor,” and the corresponding Roman 
numeral.  Once a factor is proteolytically cleaved, and thus transformed from a zymogen to a 
functional enzyme, a, for “active,” is added to the name (e.g. fVIIa = “activated factor seven”).  
Irksomely, most clotting factor proteins are numbered in the order in which the proteins were 
discovered rather than in the order in which the proteins participate in the clotting cascade.  
For this reason the protein that binds tissue factor following tissue factor exposure to plasma, is 
factor VII (fVII), a glycoprotein made in the liver.  Though most clotting factors circulate in 
plasma only in the zymogen form, approximately 1% of human fVII in in plasma is in the 
already-active enzymatic form.65  The coalescing of fVII(a)i and tissue factor make the (TF:VIIa) 
complex.  The (TF:VIIa) complex is essentially one enzyme of which tissue factor is a regulatory 
                                                             
h Vitamin K-dependent γ-carboxyglutamate-rich (GLA) domain 
i Tissue factor can bind active fVIIa or, once bound to tissue factor, fVII can be converted to fVIIa 
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subunit and fVIIa an enzymatic one.  It is this (TF:VIIa) enzyme that triggers clotting.  The 
complex can bind and cleave either Factor IX or Factor X to fIXa or fXa, respectively.  fIXa’s 
partner is fVIIIa, and the (fIXa:fVIIa) complex—like the (TF:VIIa) complex—can cleave fX to make 
fXa.  Despite there being two mechanisms by which to generate fXa (by TF:VIIa or IXa:VIIIa), 
mutation to or knockout of fIX(a) or fVIII(a) cause the hemophiliasj Bk or A, respectively.  
Hemophiliacs tend to bleed spontaneously from synovial tissues where tissue factor abundance 
is low.57   
 
The fXa accumulated from both reactions (TF:VIIa + fX   fXa; IXa:VIIa  + fX    fXa) adjoins fVa.  
When (fXa:fVa) combines with prothrombin on a membrane surface, prothrombin is cleaved to 
release the active enzyme to which the name thrombin is given.  Thrombin is a vehement serine 
protease.  Once generated, thrombin 1) frees fibrin for polymerization into a meshwork, 2) 
stabilizes platelet adhesion by activating platelet membrane receptors, and 3) activates many 
other proteins retroactive to itself in the clotting cascade.  
Enhancing and Securing Fibrin Clot Structure 
PolyP strengthens fibrin clot structure through multiple mechanisms.53  Addition of polyP to 
clotting reactions causes an early burst of thrombin production15 in the cascade, and thrombin 
modulation is known to affect clot structure.68  Additionally, Smith et al. have seen that polyP, 
when added to clotting reactions, becomes incorporated into the fibrin fibrils, visibly thickening 
the meshwork.18  Pyrophosphate competes with polyP in incorporation.  Plasminogen is a 
fibrinolytic enzyme, and tissue-type plasminogen activator (tPA) is given to patients who have 
just suffered stroke or heart attack in attempt to breakdown the blood vessel clot.  When polyP 
is incorporated into the clot structure, plasminogen and tPA are unable to bind partially-
degraded fibrin effectively.19  Thrombin-activatable fibrinolysis inhibitor (TAFI), on the other 
hand, is an enzyme that proteolytically modifies fibrin to a form that is difficult for proteases to 
                                                             
j Hemophilia is an ancient term, even mentioned in the Talmud.  Translated for meaning, the word is “tending to 
bleed.66” 




catabolize, and thrombin is responsible for activating this protein.  The early thrombin burst 
polyP elicits allows TAFI extended time during which to fortify fibrin.15  
Tissue Factor Pathway Inhibitor (TFPI) is Checked by PolyP 
To prevent our body from being in a constant state of thrombosis, our cells also express 
anticoagulant proteins.  One of these proteins is called Tissue Factor Pathway Inhibitor (TFPI), 
and as its name suggests, TFPI primarily inhibits clotting’s initiation phase via tissue factor 
pathway activation.  TFPI, most of which is secreted by endothelial cells,69 has three Kunitz 
domainsl: K 1-3.  K2 can bait fXa70  (reversible) alone or fXa in complex with other proteins.  K1 
can bait VIIa once a (TF:VIIa:fXa) complex has formed with K2 attached to fXa.71  fVa, the 
binding partner of fXa, can join the TFPI:(TF:VIIa:fXa) complex, forming an inactive, membrane-
bound TFPI:(TF:VIIa:fXa:fVa) complex.   
 
Another way TFPI stymies coagulation is by binding complexes of incompletely-hydrolyzed fVa 
bound to fXa.  Platelet-released fVa and fXa-cleaved fVa are often partially-hydrolyzed versions 
of fVa.  When fXa is attached to fully-activated fVa, on the other hand—especially in the 
presence of prothrombin (fXa:fVa:prothrombin)—TFPI becomes an ineffective fXa inhibitor.72  
The polyanionic carbohydrate heparin increases TFPI’s rate of fXa inhibition.73, 74  PolyP, though 
also anionic, is able not only to abrogate TFPI’s inhibition of (incompletely-hydrolyzed fVa:fXa) 
complexes,75 but also dampen TFPI’s global effect by increasing the rate at which functional fVa 
is generated.15, 16 
fV   fVa 
FVa is the protein cofactor of fXa.  When fVa and fXa assemble on a membrane, the resultant 
(fVa:fXa) complex is called the prothrombinase complex because (fVa:fXa) cleaves the zymogen 
prothrombin to thrombin.  Most fV is plasma-derived, but about 20% of fV comes from platelet 
α-granules.  Without fVa, fXa processes prothrombin relatively slowly,76, 77  and fV is no 
substitute for fVa in this complex.76  Though fXa itself can cleave fV to fVa,78 the poor binding of 
fV to membrane-bound fXa probably excludes fXa activation of fVa as the physiologically-
                                                             




important source of fVa.79  If fXa is not the physiologically germane protease to activate fV, one 
wonders what the relevant protease may be.   
 
(TF:VIIa),80 non-specific platelet proteases,81 calpain,82 meisothrombin,83 and neutrophil 
elastases84, 85 can hydrolyze fV, but the fVa that arises from these processes is not necessarily 
fully-functional fVa and partially-hydrolyzed fVa is easily quelled by TFPI.  Thrombin is an 
excellent fV activator, and computational models of blood clotting predict that the initial 
formation of fVa is catalyzed by α-thrombin.86  The “Factor V Activation Paradox” is that, 
according to models that use current activation rate and threshold concentration 
measurements, primary-phase thrombin generation is clearly reliant upon fVa 
generation…which absolutely necessitates prior thrombin generation.86   
Something(s) may be missing from the model.   
1.3.2.3    FVa & PolyP 
In terms of increasing fVa generation, polyP can enhance thrombin’s back-activation of fVa.15  
Both polyP and platelet-derived fV are secreted from platelet granules (- and α-, respectively), 
and platelet fV is described as slightly more amenable to the clotting process than is plasma-
derived fV.  Using plasma clotting assays, Smith et al. concluded that polyP is also able to 
enhance fV activation by factor Xa—a protein upstream of thrombin.  Recently, work has 
demonstrated that fXIa—a protein that straddles both the tissue factor and contact pathways 
of clotting—can generate fVa, allowing for formation of an active (fVa:Xa) complex in human 
plasma.87  Platelet-sized polyP is now known to potently accelerate fV activation by this fXIa.88   
 
Platelet--granule polyP in clotting reactions effects changes and accelerates enzymatic 
reactions.  Developing tools to quantitatively measure physiologic local concentrations of polyP 
in and around thrombi is on-going investigation in the Morrissey lab. PolyP’s role in hemostasis 
may or may not be the scissors to the fVa Möbius strip, but polyP is nonetheless worth adding 




1.4   Pathological Clot Formation and Inflammation 
The clotting system is complex concert: many cells, multiple surfaces, a myriad of enzymes and 
small-molecules, and factors back-activating other factors.  Each entity is a unique contributor, 
each entity is a potential liability.  Ischemic heart attack and stroke are pathological 
manifestation of inappropriate coagulation in arterial vasculature.  A pulmonary embolus (PE) is 
a venous thrombus that has broken free from somewhere else in the body and become lodged 
in an artery in the lung.  Disseminated Intravascular Coagulation (DIC)m is a life-threatening 
complication of cancers, severe trauma, snake bites, preeclampsia, and septicemia among 
others.  DIC is complete systemic failure of hemostasis.  First, unwanted blood clots form in 
small blood vessels throughout the body, preventing blood flow to organs and thus causing 
organ ischemia.  Generation of the disseminated thrombi simultaneously depletes the body’s 
supply of platelets and clotting factors so that other areas in the body begin to hemorrhage.  
 
Many of the clotting factors described in the previous sections do participate in the clotting that 
occurs pathologically; however, a growing body of literature is changing the ontological view of 
hemostasis and thrombosis as one entity.  Rather than just hemostasis in the wrong place, 
thrombosis might be a fundamentally disparate process.   Especially more characteristic of 
pathological clotting than hemostasis, is heavy engagement from the immune system.  
Distressed monocytes can express procoagulant proteins.  Plasma contact protein activation 
during microbial invasion initiates both cytokine release and the contact pathway of blood 
clotting.  Parsing the separate steps in thrombosis and hemostasis one day may provide 
information used in the development of drugs that impede thrombus formation without 
debilitating hemostasis.    
1.4.1:       ATHEROSCLEROSIS89 
Typically, circulating leukocytes do not express tissue factor on their surfaces.  Monocytes and 
macrophages can be induced to express tissue factor, however, in defense against invading 
attacking organisms.59  Precipitating clotting is a method by which to stop blood flow and trap 
                                                             
m The name Consumptive Coagulopathy is sometimes used. 
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the invading organisms.  Sometimes, however, leukocytes can be prompted to express tissue 
factor on their surfaces in an inflammatory response, even when no invading organisms are 
present.90-94  Leukocyte activation is a start of atherosclerosis and thrombosis, the causes of 
ischemic heart attacks and strokes.   
 
When you have an excess of LDL (such as when your physician tells you that you have high “bad 
cholesterol”), some of these particles will sink into sub-endothelial space within the tunica 
intima (lining of the blood vessel lumen).  Reactive oxygen species (ROS) can oxidize the lipids.  
The monocytes recognize the oxidized lipoproteins as problematic, and in response, 
phagocytose the lipoproteins via a scavenger receptor.  As LDL accumulates, the number of 
monocytes in the area of blood vessel, between the endothelial and the basement membrane, 
increases and becomes a plaque.  
 
These monocytes are expressing tissue factor on their surfaces.  Instead of having tissue factor 
separated from blood by many protective laminae, procoagulant tissue factor is present now 
only one tissue layer below the blood clotting proteins and platelets.  Each time the heart 
beats, the artery stretches.  With physical exertion, such as exercise, the artery may stretch 
enough to rupture the plaque, exposing the monocyte-derived tissue factor to the flowing 
circulation and, thus, to the clotting factors.  As a result, a clot forms in the lumen.  The first clot 
may not be large enough to block the entire artery.  The process can repeat, however, and the 
clot becomes progressively larger.  On the last beat, the clot occludes the artery and stops 
blood flow, and the person has a heart attack or stroke.   
 
Endogenous changes in cellular protein expression are not the only elicitors of thrombus 






1.4.2:       THE CONTACT PATHWAY 
Why does blood sitting in a test tube eventually clot?  One might guess that tissue factor 
contaminant from venous puncture plays a role, but physicians and scientists have noticed for 
over a half a century that substances like glass tubes, clay, and ellagic acid all cause blood to 
clot, too.  Even today, the activated partial thromboplastin time test (aPTT test)—one of the 
two most common tests for monitoring anticoagulant therapies or measuring clotting factor 
deficiency—is performed by adding kaolin,n phospholipid, and calcium to a patient’s citrated 
plasma sample and recording the time-to-clot.  Blood coagulation initiated by contact with 
these nonphysiologic sources proceeds not through the tissue factor pathway of blood clotting, 
but through contact activation/the intrinsic blood clotting pathway.   
 
In humans the contact system consists of a protease cascade whose members loop through and 
connect to steps within the tissue factor coagulation pathway and the immunological kinin—
kallikrein system [Figure 1.2].  In the first circle fXIIo is activated by an artificial surface (or 
negatively-charged surface).  FXIIa proteolyzes plasma prekallikrein (PK) to the active enzyme 
kallikrein.  Kallikrein, with high-molecular-weight kininogen, activates more fXII to fXIIa in a 
feed-forward direction.  A downstream product of the kinin-kallikrein system is bradykinin, an 
effector molecule that elicits various proinflammatory responses, including vasodilation and 
upregulated neutrophil chemotaxis.95  In the coagulation loop fXIIa activates its own zymogen 
to produce additional fXIIa.  It also activates fXI to fXIa.  fXIa cleaves fIX to fIXa, tying the contact 
activation pathway of clotting to the rest of hemostasis.  We know now also that fXIa can 
activate fV87 and thrombin can activate fXIa, and that these reactions are enhanced by polyP of 
the size released from platelets.88, 96   
  
                                                             
n The US’s main kaolin deposits are located in the state of Georgia, from Macon to Augusta.   
o Hageman factor: named for the railroad brakeman who had prolonged clot times but no visible signs of 
hemorrhagic complications.   
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1.5   Biological Implications for the Contact Pathway 
1.5.1:       EVOLUTIONARY ADVANTAGE, PERHAPS? 
What has long been a mystery is why humans have evolved to have a clotting system initiated 
by contact with artificial materials.  FXII appears in vertebrate genomes after tetrapodia.  
Marine mammals like whales and dolphins lack fXIIa, but carry its pseudogene.97, 98  Birds have 
lost fXIIa, relying instead on a paralog fXII-like protein, hepatocyte growth factor activator 
(HGFA),98, 99 which humans also have.  The serine proteases of the contact system (fXII, PK, and 
fXIp) are structurally distinct from the Vitamin-K dependent serine proteases of the tissue factor 
pathway (fVIIa, fIXa, and fXa) and thrombin98; furthermore, humans with fXII deletions or 
defects have no bleeding tendencies,100 and ΔfXII mice101 have decreased incidences of 
thrombosis.102   Additionally, estrogen increases plasma fXII levels, and women on hormonal 
contraceptives are prone to stroke.  Ex vivo contact activation is also a serious concern when 
designing medical devices.  A recently-developed antibody against fXIIa shows potential for 
preventing thrombosis without disrupting hemostasis.103 
 
So why, then, would we have evolved an unnecessary protein cascade that predisposes us to 
death by thrombosis?  There seem to be clues in case studies, mouse models, and microbial 
triggers.  Individuals with deficiencies in contact proteins have increased susceptibility to 
bacterial infection.104  Platelet aggregates and perturbed leukocytes support contact activation.  
Neutrophils can be slow in a one-on-one chase with bacteria; in order to catch fast-moving 
bacterial invaders, some neutrophils will expel their own DNA and histones, making their own 
bacteria seine.  These Neutrophil Extracellular Traps (NETs) are procoagulant via the contact 
activation pathway.  Aggregated platelets, E. coli and S. typhimurium surface proteins,105 
                                                             
p FXIa is depicted often as a member of the contact activation system rather than as a player in the tissue factor-
mediated pathway of clotting, but pictorial revisions may need to be made.  Early experiments showed that fXI is 
activated by fXIIa and thrombin.  The activation of fXI to fXIa by thrombin, however, was described as a slow 
reaction, one that needed to an anionic surface to become a physiologically-relevant step.  A truly paradigm-
shifting finding, then, was that polyP of the size released from platelets can act as an anionic surface for thrombin-
mediated fXIa activation, increasing the reaction ~3,000x.  [Choi, Smith, & Morrissey (2011)]  This may explain why 
people with fXII deficiencies show no signs of bleeding while people with fXI deficiencies can have no-to-severe 
bleeding phenotypes.  FXIa deficiency results in Hemophilia C. 
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aggregated proteins, microparticles, diatomaceous earth, glycosaminoglycans, 
lipopolysaccharide, and RNA can activate the contact system.  Platelet-sized polyP is a weak 
contact pathway activator at best.17 
 
Long-chain polyP of the sizes found in bacteria (hundreds-to-the-thousands of phosphates 
long106), however, potently activates the contact pathway,17 and long-chain polyP is also more 
effective than platelet-sized polyP in inducing thick fibrin fibril formation.  Literature searches 
have not revealed identities of microbes that secrete polyP the way that mast cells and 
platelets do, but secreting polyP may be a luxury of living in a controlled environment.  We 
know that dying mitochondria educe coagulation and also contain polyP.  It is not difficult to 
imagine a scenario in which polyP leaks from pathogen casualties during a skirmish with 
immune cells.  Of Interest, both Neisseria meningitides 107 and Neisseria gonorrhoeae108 are 
covered by long-chain polyP capsules.  Because polyP is a metal chelator, some researchers 
hypothesize that Neisseria may use their capsular polyP as a pseudo-siderophore, stealing iron 
from host transferrin.109   
1.5.2:       SYSTEM RECOGNITION 
Most importantly and backed by evidence is that the blood coagulation system can distinguish 
bacterial-sized polyP (contact activation) from platelet-sized polyP (hemostasis).  How the 
system recognizes one from the other is unknown.  One way our bodies might be able to tell 
self from non-self polyP is through polyP’s complexion with various metals.  Though we like to 
graphically represent polyP as a linear, ball-and-string free-floating molecule, polyP is almost 
always complexed with metals and, likely, carries at least secondary, if not transiently-
crystalline structure.  We have seen that polyP binds differently to different metals (Chapter 3), 
and our collaborators, Donavan et al., have synthesized polyP granules, modulating the 
granules’ structures and sizes by changing the metal composition added to long-chain-polyP 
during particle formation.  Members of the Liu lab (UIC-Chicago) also think that the formation 
of granular—or acidocalcisome-type—polyP may be occur through a downhill-energy 
mechanism, much like protein folding.  Microbes sequester various types of metals in response 
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to toxicity and environmental conditions and store these metals with polyP in acidocalcisomes.  
Many of these metals (Pb, Cd, etc.) are not detected within platelets.  If polyP arrangement 
with metal complexation changes with metal composition, perhaps polyP secondary structure 
or spacing is what our clotting proteins truly recognize.   
 
Bock et al. (1981) Biochem. saw that stripping metals from ellagic acid—a potent contact 
pathway activator—abrogated the molecule’s procoagulant activity,110 and by adding different 
metals to ellagic acid, they were able to modulate procoagulant response to the molecule.  
Similarly, Dr. S. A. Smith has found that polyP has different affinities for certain coagulation 
factors in the presence of different metals.  Recent research between our lab (Dr. R. Travers & 
R. Breitenfeld) and the Esmon lab has focused on testing and understanding the binding of 
putative anti-polyP antibodies to various sizes of polyP.  In preliminary studies one antibody 
(PP2059) does seem to bind preferentially to longer-chain polyP.  An antibody that 
discriminates long-chain from platelet-sized polyP could potentially serve as therapeutic agent 
against sepsis-induced coagulopathy. 
1.5.3:       POTENTIAL OF POLYP (INHIBITORS) AS A THERAPEUTIC AGENT 
Because platelet-sized polyP accelerates clotting rather than initiates it, platelet polyP is being 
considered as a potential anticoagulant target.   Clotting is a threshold event, and by inhibiting 
polyP, one might be able to globally increase the protein concentrations needed to initiate the 
clotting cascade without extinguishing hemostatic protein function.  Many current 
anticoagulant drugs come with severe bleeding risk, often because these drugs obliterate the 
functions of central clotting cascade proteins.  Warfarin, for example, disallows critical 
posttranslational modifications to central clotting factors.  Heparin, a quintessential 
anticoagulant, indirectly increases inhibition of fXa and thrombin.  Heparin binding to certain 
platelet proteins, however, can cause autoimmune reactions.  Exogenously-added polyP to 
plasma seems to be able reverse the anticoagulant effects of heparin.111  The observation that 
mice are equally protected from thrombosis with anti-polyP agents and heparin,50 but have 
reduced bleeding side effects with anti-polyP agents, may be partly attributable to polyP’s role 




Patients with -granule storage disease, however, do present with bleeding diatheses.  When 
Ghosh et al. knocked out inositol hexakisphosphate kinase 1 (IP6K1) in mouse model, they 
found that the platelet polyP in the mice was greatly decreased.  The ΔIP6k1 mice were 
protected against thrombosis but had slowed platelet aggregation and extended bleeding 
times.112  The increased bleeding time is attributed primarily to platelet polyP depletion, 
through a platelet-mediated mechanism.  Little is known currently about the function of 
physiologic phytic acid (IP6) and phytic acid derivatives, though, much less their ties to blood 
clotting and polyP.  Developing anti-long-chain-polyP drugs against to combat sepsis-induced 
thrombosis might be advantageous.  Conversely, exogenous polyP shows promise111 as 
anticoagulant reversal agent with a short half-life in biological fluid.15 
1.6   Scope of this Work: PolyP Degradation in Biologic Fluids 
 
The reverse of polyP synthesis is, of course, polyP catabolism.  Understanding the mechanism(s) 
by which poly is degraded in human serological fluid the focus of my work in the Morrissey lab.  
If polyP is an important molecule in clotting, then any entities—such as enzymes or metals—
that regulate the molecule’s appearance and disappearance in blood must be important factors 
in hemostasis and thrombosis, too.  My work in the Morrissey is comprised of two related 
stories: 1) creating polyphosphatase substrates that can be used for enzyme identification in a 
high-throughput manner and 2) identifying the cause of polyP degradation in serum.   
1.6.1:       PART I : SYNTHESIZING POLYPHOSPHATASE SUBSTRATES 
We knew that polyP was somehow degraded by entities contained within human plasma and 
serum.15, 113  Presumably, these entities would be phosphatases.  For the first part of my 
project, I synthesized new chemical species (substrates) that would allow us to efficiently and 
more-easily monitor polyP degradation in real time.  Discovering I could esterify the ends of 
polyP through coupling chemistry, I was able to attach a chromogen to the ends of polyP.  
Structural confirmation of the indicator’s attachment to polyP was designed and carried out by 
Dr. Y. Wang.  In proof-of-principle experiments I tested the indicator’s functionality using 
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proteins that are known to degrade polyP and found that the indicators worked as hoped.  
Next, I used the indicator to show that a protein called Nudt2—found overexpressed in some 
breast cancers—has previously-undescribed endopolyphosphatase activity.  Using the EDAC-
coupling reaction, C. J. Baker synthesized a fluorogenic substrate version that surpassed the 
chromogenic ones in sensitivity, as determined by the reduced substrate concentrations 
needed to spectrophotometrically follow polyP cleavage.   
1.6.2:       PART II: DETERMINING THE MECHANISM(S) OF POLYP DEGRADATION IN SERUM 
The second piece of work has involved testing established hypotheses of how polyP 
degradation occurs in biology.  The project was designed to identify the polyphosphatases 
responsible for polyP degradation in serum (as a blood surrogate).  What we found was that 
polyP decay in serum or plasma is dominated by Ca2+-mediated chemical hydrolysis, providing 
an intrinsic, chemical mechanism for limiting polyP function extracellularly.  These findings 
could be profoundly significant, possibly providing an explanation for the necessarily acidic 
nature of acidocalcisomes, in which metal ions and polyP are stored together. We believe that 
the mechanisms of polyphosphate degradation may be consequential not only for human blood 




1.7   Figures 
Figure   1.1:      Polyphosphate Structures 
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CHAPTER 2: SYNTHESIS AND EVALUATION OF CHROMOGENIC AND FLUOROGENIC 
SUBSTRATES FOR HIGH-THROUGHPUT DETECTION OF ENZYMES THAT HYDROLIZE 
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2.2       Introduction 
2.2.1:       POLYP 
Inorganic polyphosphates (polyP) are linear polymers of orthophosphate joined by high-energy 
phosphoanhydride bonds and can range in length from tens to thousands of phosphates. PolyP 
is widespread throughout biology and implicated in a multitude of physiologic processes in 
organisms from bacteria to man,1-4 though many of its biological functions likely remain to be 
discovered and characterized.  PolyP is also an industrial chemical with applications in areas 
such as water treatment, food processing, fertilizers and flame retardants.3  PolyP’s 
biodegradable nature makes polyP attractive for a multitude of uses, and it would be important 
to understand how polyphosphates are turned over enzymatically.   
2.2.2:       (POLY)PHOPSHATASES 
2.2.2.1       Exo- Polyphosphatases 
The in vivo lifetime of polyphosphate-containing molecules is undoubtedly affected by 
enzymatic hydrolysis.  For simplicity, we generalize polyphosphatase activity into one of two 
categories: exo(poly)phosphatase degradation or endopolyphosphatase cleavage.  Exo(poly) 
phosphatases bind the ends of unfettered chains and work processively to free 
monophosphates from the chains.  Endopolyphosphatases would hydrolyze internal 
phosphoanhydride bonds.1 Although some of the enzymes responsible for degrading polyP 
have been identified in unicellular organisms, they remain relatively poorly studied in higher 
37 
 
eukaryotes, with some notable exceptions.1, 5  Two examples of exopolyphosphatases are the 
human protein, h-prune, a short-chain exopolyphosphatase implicated as a regulator of 
metastasis6; and mammalian alkaline phosphatase,7 a highly potent exopolyphosphatase used 
often for dephosphorylating DNA.  Recent work has shown that polyP of the length secreted 
from activated human platelets8 is degraded in human plasma with a half-life of about 90 min.9  
 
2.2.2.2       Endo- Polyphosphatases 
Less well-characterized than their counterparts are endopolyphosphatases. The 
endopolyphosphatases so far confirmed seem to be a disparate lot, differing in metal 
dependence, pH preference, mass, cellular location, tissular expression, and chain length 
specificity.  The proteins identified so far as endopolyphosphatases are members of the Nudix 
superfamily: hydrolases that catabolize nucleoside diphosphates linked to other moieties, X.  
 
NpnNs are PolyP chains capped on each end with a nucleotide (5’—5’).  The tether between 
these nucleotides ranges from two to seven phosphates long.  Perplexingly, the biological 
effects of these molecules are simultaneously marked and diffuse.  Separately, both PolyP and 
NpnN concentrations affect metal chelation, Fenton chemistry, platelet aggregation, bone 
mineralization, toxic metal export, blood clotting, pathogenic virulence, protein activation, cell 
proliferation, DNA damage, receptor inhibition, cardiac muscle regulation, vesicle osmolarity 
control, vascular tone, platelet aggregation, neurotransmission, purinoceptor binding, cell 
signaling.   
 
2.2.2.3       Clinical Significance 
Interestingly, recent review10 and study of number of Nudix proteins has exposed this 
superfamily’s proclivity towards substrate mutability with a dependence on environmental 
factors.  Perhaps unsurprisingly, the expressional dysregulation of some human Nudix 
hydrolases is linked to disease states.11-13  Exactly how and to what extent PolyPs and NpnNs 
impact so many processes in vivo is still somewhat unclear.  Also open for further investigation 
is how the phosphomolecules themselves are synthesized, modulated, circulated, and recycled.  
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Being able to recognize, and ultimately understand, how distinct phosphatase activities control 
PolyP and NpnN degradation may have clinically-significant implications. 
2.2.3:       CURRENT METHODOLOGIES  
An impediment to identifying and studying the properties of polyP-degrading enzymes has been 
the dearth of high-throughput means for detecting inorganic polyphosphatases and quantifying 
their activities.  Many of the existing methods for quantifying enzymatic polyP degradation are 
cumbersome, of low sensitivity, or require the use of specialized equipment. The methods also 
typically rely on multiple steps including chromatography, gel electrophoresis, laborious 
physical extraction protocols coupled with chemical detection of liberated inorganic 
orthophosphate, or the use of radiolabeled polyP.1  One recently reported exception was the 
facile method used for detecting exopolyphosphatase activity by the continuous recording of 
released inorganic monophosphate to determine the kinetic parameters of the 
exopolyphosphatase, h-prune.6  Detecting and quantifying the action of endopolyphosphatases 
has been substantially more time-consuming, however, as it typically involves resolving the 
digested polyP products using gel electrophoresis14 or optimizing coupled reactions with non-
commercially-available enzymes.  We therefore sought to develop chromogenic and 
fluorogenic polyP substrates that would allow polyP degradation to be followed 
spectrophotometrically and in particular, a method that would allow high-throughput detection 
of endopolyphosphatase activity [Figure 2.1].  Ideally in our design, we would covalently attach 
chromogenic or fluorogenic dyes to the terminal phosphates of polyP. Chromogenic and 
fluorogenic compounds are readily available, and chromogenic and fluorogenic substrates have 
been uses successfully for a number of hydrolases.  These types of substrates are adaptable for 
use with high-throughput assays in multi-well formats.  
2.2.4:       POLYP CHEMISTRY 
We previously showed that primary amines can be covalently coupled via phosphoramidate 
linkages to the terminal phosphates of polyP in a reaction promoted by the zero-length 
crosslinking reagent, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC).15  EDAC is also 
used in protein-coupling chemistry and carboxylic acid conjugation.  In the present study, we 
39 
 
now show that EDAC can also be used to promote the efficient formation of phosphoester 
linkages with the terminal phosphates of polyP, and we apply this chemistry to create 
chromogenic or fluorogenic polyphosphatase substrates in which polyP is end-labeled with 
either 4-nitrophenol (NOL) or 4-methylumbelliferone (MU).  This reaction adds to the known 
coupling chemistry for polyphosphates, permitting facile covalent linkage of alcohols with the 
terminal phosphates of inorganic polyphosphate.  We show with the substrates made, we can 
detect the action of endo- and exopolyphosphatases, depending on assay configuration. 
Additionally, this report identifies Nudt2 as having inorganic-polyphosphatase-hydrolytic 
activity in addition to an Ap6A-cleaving activity. 
2.3       Results 
2.3.1:       ESTERIFICATION OF POLYP’S TERMINAL PHOSPHATES WITH METHANOL 
EDAC has been used to promote the formation of ester linkages between alcohols and 
carboxylates,16 as well as phosphoester linkages between alcohols and certain organic 
phosphates.17 We therefore examined if EDAC could promote the formation of ester linkages 
between alcohols and the terminal phosphate groups of inorganic polyP [Figure 2.2].  
 
For a proof-of-principle experiment and to identify reaction conditions more readily, we first 
examined EDAC-mediated esterification of polyP with methanol. The reaction resulted in a 
product that was protected from exopolyphosphatase (CIAP) digestion to an extent comparable 
to polyP that had been end-labeled with spermidine via phosphoramidate linkages (Table 2.1). 
 
We used solution-state NMR to further verify the product’s identity. In the 31P spectra, 
unmodified polyP displayed a relatively broad alpha (terminal) phosphorus peak at about 7 ppm 
[Figure 2.3, part A]; the broadness likely reflects exchange of protonation states of the 
phosphate group. 
 
Methylated polyP displayed an alpha peak shifted to 9.4 ppm [Figure 2.3, part B], which was 
also much sharper than the alpha peak of underivatized polyP. The methylated polyP alpha 
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peak sharpness likely is caused by attenuation of the exchange broadening. This shifted alpha 
peak displayed as a doublet [Figure 2.3, part C] owing to the 31P -31P J-coupling between the 
alpha- and beta-phosphorus atoms. We next utilized the 3JH-P coupling between the methyl 
protons and alpha-phosphorus atom to confirm end modification and map connectivity. When 
proton decoupling was turned off, each peak of the alpha phosphorus doublet signal was split 
into a quartet pattern [Figure 2.3, part D], indicating the presence of three neighboring protons. 
To assign the chemical shift of the methyl protons, we acquired a 1D 1H spectrum with 
heteronuclear decoupling irradiation at the alpha phosphorus frequency. The resulting 
spectrum, when compared to the spectrum without decoupling (compare [Figure 2.3, part E] 
and [Figure 2.3, part F]), shows that the peak at around 3.5 ppm is converted from a doublet to 
a singlet. This transformation is consistent with a proton signal being coupled to a single 
neighboring phosphorus atom.  To identify the carbon signal of the methyl group, we used 13C-
enriched (20%) methanol to synthesize methylated polyP. The resulting 1D 13C spectrum [Figure 
2.3, part H] shows significant enhancement of the carbon peak at ~53.6 ppm, which was almost 
unobservable in natural abundance methyl-polyP preparation [Figure 2.3, part G].  To confirm 
that coupling existed between the carbon peak and the previously identified methyl proton 
signal, we performed 2D 1H-13C HSQC on the 13C-enriched sample, with clearly observable 
correlation between the two signals [Figure 2.3, part I]. 
2.3.2:       POLYP END-LABELED WITH NOL OR MU 
NOL is used often in making chromogenic substrates, as its absorption spectrum shifts 
dramatically when ester-linked to carboxylates or a single phosphate. MU is also extensively 
employed in synthesizing fluorogenic substrates because its fluorescence is quenched when 
ester-linked to carboxylates. Reacting polyP with NOL and EDAC resulted in a polyP preparation 
that was nearly as resistant to CIAP digestion as was polyP end-labeled with spermidine or 
methanol (Table 2.1). Reacting polyP with MU and EDAC resulted in a product with even 
greater CIAP resistance (Table 2.1) than that of polyP derivatized with spermidine or methanol. 
Absorption spectra of polyP-NOL before and after hydrolysis reveal an absorption maximum of 
285 nm before hydrolysis (indicating covalent coupling of the NOL dye to phosphate) and 




Analyzing polyP-NOL by 1D 31P-NMR produced an alpha peak shifted from ~7 ppm in 
underivatized polyP [Figure 2.3, part A] to a doublet at ~17 ppm in polyP-NOL [Figure 2.5, part 
A], consistent with covalent modification of the terminal phosphates. Resolving polyP and 
polyP-NOL by gel electrophoresis indicated little change in the distribution of polymer lengths 
after reacting the polyP with NOL and EDAC [Figure 2.5, part B]. 
2.3.3:       EXOPOLYPHOSPHATASE (CIAP) DIGESTION OF POLYP-NOL 
End-labeling efficiency was calculated after complete acid hydrolysis of polyP-NOL and 
quantification and comparison of liberated NOL and monophosphate ratios (and assuming a 
mean polymer length of 50 phosphates). Using a polyP-NOL preparation in which approximately 
40% of the polyP molecules were singly end-labeled, we added CIAP and monitored A400 versus 
time at 37 oC [Figure 2.5, part C]. These results show that singly-labeled polyP-NOL can be used 
to follow the progress of exopolyphosphatase digestion. The curvilinear progress curves 
probably reflect the fact that the substrate is ~50 phosphates long but the chromophore is 
released only when the last phosphate is removed from the substrate. 
2.3.4:       ENDOPOLYPHOSPHATASE DIGESTION OF POLYP-NOL AND POLYP-MU  
Covalent modification of polyP on both ends protects polyP against exopolyphosphatase (CIAP) 
digestion (Table 2.1). We therefore reasoned that two-stage assays for endopolyphosphatase 
activity could be devised using polyP that is completely labeled on both ends with chromophore 
or fluorophore [Figure 2.1]. Digestion by exopolyphosphatase should be possible only after the 
action of endopolyphosphatase has exposed free polyP ends. In such an assay one could 
employ either sequential or simultaneous digestion with endo- and exopolyphosphatases. 
Accordingly, polyP-NOL was predigested to completion with SAP to eliminate singly-labeled 
molecules, after which the polyP-NOL was repurified. We then used this SAP-treated polyP-NOL 
in a two-stage endopolyphosphatase assay in which we first digested the substrate with either 
Nudt3 (a hydrolase with known endopolyphosphatase activity14) or Nudt2 (another nudix 
hydrolase that cleaves dinucleotide polyphosphates, NpnNs, but whose endopolyphosphatase 
activity was not known) and then monitored product release during digestion with CIAP.  Figure 
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2.6 shows that few dye molecules from SAP-treated polyP-NOL were released upon incubation 
of the substrate with either endopolyphosphatase (Nudt2 or Nudt3) or with 
exopolyphosphatase (CIAP) alone; however, polyP-NOL was readily hydrolyzed by CIAP 
following pretreatment with either Nud2 or Nudt3. Additionally, this experiment demonstrated 
that Nudt2 has endopolyphosphatase activity [Figure 2.6, part B]. 
 
The efficiency of polyP labeling with MU was usually greater than that with NOL (Table 2.1), so 
predigestion of polyP-MU [Figure 2.7, part A] with SAP was typically not required before using 
this substrate to detect endopolyphosphatase activity.  Figure 2.7, part B shows the reaction 
curves for two-stage assays of polyP-MU digestion with Nudt2 followed by CIAP.  Neither Nudt2 
nor CIAP alone released significant MU, while polyP-MU was efficiently digested by CIAP after 
incubation with Nudt2.  
 
This experiment also demonstrates the amount of CIAP required for maximal rates of product 
release.  Figure 2.7, part C shows a much shorter time course of the second stage of this two-
stage assay, using saturating levels of CIAP.  We tested Nudt1 (a nudix hydrolase known to 
cleave Ap3A but not long-chain NpnN molecules) in a similar two-stage assay, but under the 
various conditions we used, the enzyme did not support MU release by CIAP (data not shown). 
We also examined a one-stage assay employing polyP-MU incubated simultaneously with CIAP 
plus varying concentrations of Nudt2. We found limited product release with CIAP alone but 
robust product release by the combination of CIAP and Nudt2 [Figure 2.7, part D]. 
2.4       Discussion 
This study had two goals: expand the covalent coupling chemistry for polyP, allowing for facile 
linkage of alcohols to the terminal phosphates of polyP via phosphoester bonds; and use this 
chemistry to develop high-throughput methods for detecting and quantifying the enzymatic 
digestion of polyP. We now report that the water-soluble cross linker, EDAC, can be used to 
efficiently generate phosphoester linkages between alcohols and the terminal phosphates of 
polyP. We utilized this coupling chemistry to generate new chromogenic and fluorogenic 
substrates for detecting the enzymatic hydrolysis of polyP, based on phosphoester end-labeling 
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of polyP with NOL or MU, respectively. Additionally, with our polyP substrates, we were able to 
monitor and distinguish endo- and exopolyphosphatase activities in real time. 
 
Previously, we reported that EDAC could be used efficiently to couple compounds with primary 
amines to the terminal phosphates of polyP via phosphoramidate linkages, and this chemistry 
has allowed us to link a variety of probes to polyP;15 for example, we used this method to 
biotinylate polyP, which we then employed to detect and quantify interactions between polyP 
and blood clotting proteins.18, 19 Although phosphoramidate linkages are relatively stable under 
neutral and alkaline conditions, the linkages are highly acid-labile.20 It would be advantageous, 
therefore, to be able to efficiently link the terminal phosphates of polyP to organic compounds 
via phosphoester linkages, which, unlike phosphoramidate linkages, resist acid hydrolysis at 
physiological temperatures.20 A previous study used combinations of carbodiimides (other than 
EDAC) in conjunction with polyP and alcohols in anhydrous organic solvents to generate 
phosphoester linkages to polyP; however, the reactions also caused substantial polyP hydrolysis 
to much shorter polyP chains and the apparent formation of cyclic and branched polyP adducts 
(which are unstable in aqueous solution).21 In this report we identified aqueous coupling 
conditions for EDAC-mediated formation of phosphoester linkages to polyP that resulted in 
labeling just the terminal phosphates and that did not appreciably shorten the polyP chains. 
 
Full-length polyP capped on either end with chromogenic or fluorogenic dyes was used to 
detect phosphatase activity. PolyP-NOL preparations that were incompletely labeled on both 
polyP ends were useful substrates for detecting exopolyphosphatase activity, which released 
free NOL upon the complete hydrolysis of the singly end-labeled polyP. On the other hand, 
polyP-NOL and polyP-MU preparations that were fully labeled on both polyP ends were highly 
resistant to exopolyphosphatase digestion, and this property was used as the basis of a two-
stage assay in detecting endopolyphosphatase activity. In such assays, endopolyphosphatase 
digestion creates free polyP ends which are then substrates for exopolyphosphatase (CIAP) 




Not surprisingly, assays using the fluorogenic substrate, polyP-MU, could be conducted using 
lower substrate concentrations than those using the chromogenic substrate, polyP-NOL, owing 
to the greater sensitivity of fluorescence-based detection methods; however, assays using 
fluorogenic substrates require more specialized equipment and sample handling than do simple 
chromogenic assays, prompting us to develop both types of substrates in this study. 
 
We constructed a two-stage assay to demonstrate the activity of a known 
endopolyphosphatase (Nudt3), and to demonstrate that another nudix hydrolase (Nudt2) also 
exhibits endopolyphosphatase activity. Nudt3, sometimes called DIPP1, or simply DIPP, is a 
nudix-type enzyme with multiple known in vitro substrates: capped mRNA, oxo-8-dGTPase, 
inositol pyrophosphates, dinucleotide polyphosphates, and inorganic polyphosphate (reviewed 
by McLennan22). Many nudix-type phosphatases are clinically-important enzymes and their 
overexpression can be markers of disease. Nudt2 (Apah1), for example, is an Ap4A hydrolase 
that, when overexpressed in breast cancer, correlates with poor prognosis.11 In addition to 
processing Ap4A, Nudt2 can hydrolyze long-chain NpnNs such as Ap6A. We hypothesized that 
this nudix enzyme, though previously not described as having endopolyphosphatase activity on 
inorganic polyP, might be able to cleave polyP and that we might detect this cleavage using our 
substrates in conjunction with CIAP. This was confirmed with our novel substrates. Like Nudt2, 
the human short-chain exopolyphosphatase, h-prune, is also implicated in tumor survival,6 
again providing a connection between alterations in polyP degradation and human health. 
 
It should also be noted that the substrates only release a signal (free dye) when the last 
phosphate of the polyP chain is removed by an exopolyphosphatase. While this reaction was 
efficiently catalyzed by CIAP, other exopolyphosphatases might digest polyP to very short 
chains but not completely to monophosphate and therefore would not be expected to release 
the dye from these substrates. Such enzymes could be studied using these substrates in 




We anticipate that the utilization of chromogenic and fluorogenic polyP substrates will aid 
further inquiry into how polyphosphates are turned over enzymatically. For example, an 
additional class of enzymes that could conceivably be studied using these substrates includes 
kinases that utilize polyP as a substrate/phosphate donor. Also important is the development of 
a method for making stable ester linkages to the ends of polyP.  Applications for such 
phosphoester linkages could include attaching polyP to surfaces, fabricating polyP-containing 
nanoparticles, and attaching fluorescent probes to polyP, in addition to creating the 
chromogenic and fluorogenic substrates for polyP-degrading enzymes reported here. 
2.5       Conclusions 
Using carbodiimide-mediated chemistry, we selectively esterified the terminal phosphates of 
inorganic polyP polymers with various alcohols.  In a proof-of-principle experiment, we used 
methanol in esterification reactions and confirmed the product through 1D and 2D 31P, 1H, and 
13C NMR analyses.  We also showed that polyP could be similarly end-labeled with chromogenic 
or fluorogenic alcohols to form adducts.  These adducts were shown to be useful substrates for 
polyP-degrading enzymes, allowing us to monitor enzyme activity spectrophotometrically in 
real time; furthermore, we used these substrates to identify a new function for the clinically-
significant enzyme, Nudt2. The chemistry and substrates developed in this work are likely to be 
useful for synthetic and clinical applications. 
2.6       Experimental Section 
2.6.1:       MATERIALS 
Specified reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. 
NOL was recrystallized using hot water and ethanol. All experiments in this report used a polyP 
preparation (Natriumpolyphosphat P70) that was a kind gift from BK Giulini GmbH 
(Ludwigshafen, Germany). The polymer lengths of this preparation ranged from about 20 to 
100 phosphates, with a mean length of approximately 45 to 50. PolyP concentrations were 
quantified using malachite green after acid hydrolysis23 and are reported here in terms of 
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phosphate monomer (monomer formula: NaPO3). PolyP was end-labeled with spermidine via 
phosphoramidate linkages as described.15 
2.6.2:       EDAC-MEDIATED END-LABELING OF POLYP BY ESTERIFICATION WITH METHANOL  
A mixture of 5.9 mM polyP, 150 mM freshly-dissolved EDAC, and 6.4 M methanol in 100 mM 
MES buffer pH 6.5 was incubated for either 5 h at 37 °C or for 1 h at 65 °C, after which the 
reaction mixtures were cooled on ice. Reaction volumes varied from 0.35 to 6.5 mL.  PolyP-
methanol was purified by acetone precipitation; briefly, NaCl was added to the reaction mixture 
(to 535 mM) followed by two reaction volumes of acetone, with mixing after each addition. The 
mixture was then centrifuged at 11,000 x g for 7 min at room temperature, after which the 
supernatant was discarded. The polyP pellet was washed twice by adding acetone to the tube 
followed by centrifugation.  Pellets were then dried and re-dissolved in water.  
 
Prior to NMR analyses, polyP-methanol was further purified by adsorption to a suspension of 
silica particles (“glass milk”). Glass milk was produced by a modification of the method of 
Vogelstein and Gillespie,24 in which 250 mL silica (325 mesh) was stirred in 400 mL water for 
1 h, then allowed to settle for 1 h to remove large particles. The supernatant was then 
centrifuged for 4000 x g for 15 min after which the pellet was collected and resuspended in 
200 mL 50% nitric acid. This was then stirred and heated to close to boiling, after which it was 
cooled to room temperature. The silica fines were then collected by centrifugation and washed 
five times with water by resuspension and centrifugation. The final pellet of washed silica fines 
was resuspended as a 50% slurry by volume (glass milk). PolyP was purified by binding to, and 
elution from, glass milk as described,23 except that the solutions were kept chilled throughout, 
and the polyP was eluted with 95 °C water instead of buffer. 
2.6.3:       EDAC-MEDIATED END-LABELING OF POLYP BY ESTERIFICATION WITH NOL   
A mixture of 5.9 mM polyP, 150 mM freshly-dissolved EDAC, and 200 to 525 mM NOL was 
incubated for 1 h at 65 °C. Reaction volumes varied from 0.35 to 40 mL, and mixtures were 
agitated throughout, since the NOL concentrations exceeded solubility limits even in hot water. 
Completed reactions were cooled on ice and polyP was isolated by acetone precipitation. 
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Because some free NOL coprecipitated with polyP in the first acetone precipitation, three full 
cycles of acetone precipitation were employed in which the collected polyP pellets were 
completely resuspended in water and re-precipitated by addition of NaCl and acetone followed 
by centrifugation. PolyP-NOL was then further purified using Bio-Gel P-6 desalting columns (Bio-
Rad; Hercules, CA). The polyP-containing column fractions were identified by toluidine blue 
staining,25 pooled, and lyophilized. 
2.6.4:       EDAC-MEDIATED END-LABELING OF POLYP BY ESTERIFICATION WITH MU  
A mixture of 5.5 mM polyP, 150 mM freshly-dissolved EDAC, and 280 mM MU in a reaction 
volume of 1 mL was incubated for 1 h at 65 °C with agitation because the concentrations of MU 
used exceeded solubility limits.  The reactions were then cooled on ice and polyP-MU was 
isolated using acetone precipitation as described above for the preparation of polyP-NOL. 
2.6.5:       NMR ANALYSES 
Purified polyP and polyP derivatives were dissolved in water containing 10% (v/v) D2O. All 
solution NMR spectra were collected on a Varian Unity INOVA 600 MHz proton frequency 
spectrometer with a 5 mm Varian AutoTuneX 1H/X PFG Z probe at 23 °C.  1D 31P and 13C spectra 
were acquired with a 2 s recycle delay.  1D 1H spectra were acquired with a 1 s recycle delay, 
and solvent suppression was done by pre-saturation.  2D 1H-13C Heteronuclear Single Quantum 
Coherence (HSQC) spectra were acquired with 2048 and 160 points in the 1H and 13C 
dimensions, respectively.  1H and 13C spectra were referenced with external tetramethylsilane 
at 0 ppm, and 31P spectra were referenced with external phosphoric acid at 0 ppm.  1D spectra 
were processed with MNOVA (MestreLab Research), and 2D spectra with NMRPipe.26  
polyP: 31P NMR (90% H2O 10% D2O, 243 MHz): δ: -7.01 (s), -21.14, -21.65.  polyP-methanol: 
31P NMR (90% H2O 10% D2O, 243 MHz): δ: -9.36(d JP,P = 17.8 Hz), -21.67. 
1H NMR (90% H2O 10% 
D2O, 600 MHz): δ: 3.51 (d, JH,P = 11.42 Hz). 
13C NMR (90%H2O 10% D2O, 151 MHz): δ: 53.7. 





2.6.6:       GEL ELECTROPHORESIS OF POLYP  
PolyP preparations were resolved on urea-containing 15% polyacrylamide gels and visualized 
using DAPI negative staining as described.27 
2.6.7:       ALKALINE PHOSPHATASE DIGESTION OF POLYP  
Protection against exopolyphosphatase-mediated degradation was employed to determine the 
extent to which polyP molecules were doubly end-labeled, as previously described.15 Such 
digestions used calf intestinal alkaline phosphatase (CIAP, Promega; Madison, WI), a highly 
active exopolyphosphatase.7 Typical reactions included 250 µM polyP and 20 units/mL CIAP; 
the liberated monophosphate was quantified using malachite green analysis.23 
 
PolyP-NOL preparations often varied in the extent to which both ends of polyP were 
derivatized. To rid these preparations of singly-labeled polyP, some were digested to 
completion with recombinant shrimp alkaline phosphatase (SAP, New England BioLabs; Ipswich, 
MA) by incubating 50 mM derivatized polyP with 50 U/mL SAP for 2 h at 37 °C in the 
manufacturer’s buffer. SAP then was inactivated by heating at 65 °C (7 min), after which the 
remaining polyP was re-purified by acetone precipitation. These preparations were termed 
SAP-treated polyP-NOL. 
2.6.8:       ENDOPOLYPHOSPHATASE DIGESTION OF POLYP 
Certain nudix hydrolases were examined for endopolyphosphatase activity, typically in a two-
stage assay. In the first stage, polyP-MU or SAP-treated polyP-NOL was incubated with endo-
acting enzyme (Nudt2 or Nudt3, Fitzgerald Industries International; Acton, MA) in the 
appropriate buffer at 37 °C, after which the reactions were chilled on ice. Buffer conditions 
were the following: for Nudt2, 8 mM SAP-treated polyP-NOL or 2 mM polyP-MU, 50 mM HEPES 
pH 7.4, and 5 mM MgCl2; for Nudt3: 5.5 mM SAP-treated polyP-NOL or 2 mM polyP-MU, 25 mM 
HEPES pH 7.4, 20 mM NaCl, 10 mM MgCl2, and 1 mM dithiothreitol. 
 
For the second stage, a solution of CIAP in 100 mM Tris-HCl pH 8.8, 0.2 mM ZnCl2 was prepared 
and warmed to 37 °C in 96-well polystyrene plates (Corning; Tewksbury, MA). The second stage 
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was initiated by pipetting 100 μL of the chilled nudix-polyP reaction into pre-warmed wells 
containing 100 μL CIAP solutions, after which the rate of dye release was monitored 
spectrophotometrically at 37 °C. For polyP-NOL substrate, absorbance at 400 nm was measured 
using a SpectraMax M2 microplate reader (Molecular Devices; Sunnyvale, CA); for polyP-MU 
substrate, fluorescence was quantified in fluorescence mode using excitation at 360 nm, 
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NMR analyses of end-methylated polyP. 1D 31P spectra of (A) unmodified polyP and (B) polyP following reaction 
with methanol and EDAC. The terminal phosphate (alpha) peaks are indicated by arrows, and the inset in panel A is 
an expanded view of the alpha peak region of this spectrum. (C) The expanded view shows that the sharp alpha 
peak in panel B is resolved as a doublet. (D) Without 1H decoupling, the alpha peak from methylated polyP expands 
into quartets as a result of J couplings from methyl protons. (E,F) 1D 1H spectra of methylated polyP with (E) and 
without (F) applied decoupling irradiation at the alpha-phosphate frequency. The doublet peak at ~3.5 ppm (E) 
converts into a singlet (F) after irradiation because the proton peak is coupled to a phosphorus atom. (Other peaks 
in the 1H spectra are from the MES buffer used in product purification and thus not affected by the decoupling.) 1D 
13C spectra of methylated polyP prepared with (G) natural abundance methanol or (H) 20% 13C-enriched methanol. 
Use of 13C-enriched methanol in the reaction greatly enhanced the signal at ~53.7 ppm (asterisk). (Other 13C peaks 
are from the MES buffer.) (I) 2D HSQC analysis of the 53.7 ppm 
13
C peak confirmed that the 
13
C atoms are 





Figure   2.4:     Analysis & NOL Substitution Series Using UV-Vis Spectroscopy 
(A) Absorbance spectra of NOL substitution series with (B) the accompanying compounds’ chemical structures. 
Each compound (except ii) was brought to a final concentration of 150 µM in alkaline conditions (1.5M Tris-HCl 
buffer pH = 8.8, final) and scanned spectrally; NOL (ii) was scanned under acidic conditions. Absorbance maxima 
were the following: 398 nm (i), 317 nm (ii), 310 nm (iii), and 285 nm (iv). (C) Absorption spectra of polyP end-
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Figure   2.5:     Analysis of PolyP End-labeling with NOL 
(A) 1D 31P spectrum of polyP-NOL highly labeled at both ends. The alpha phosphate peak, indicated by an arrow, is 
resolved as a doublet (inset) upon axis expansion. (B) Comparison of polyP and polyP-NOL resolved by gel 
electrophoresis and detected by DAPI negative staining. (C) Enzymatic degradation of varying concentrations of 
incompletely end-labeled polyP-NOL (8 to 16 mM phosphate) by CIAP, with NOL release detected 






Figure   2.6:     Sequential Digestion of Doubly End-labeled PolyP-NOL 
In both panes doubly end-labeled polyP-NOL was first incubated with or without endopolyphosphatase (Nudt2 or 
Nudt3) for 10 or 60 min at 37 oC. Exopolyphosphatase (120 U/mL CIAP) was then added to the indicated samples 
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Figure   2.7:     Digestion of PolyP-MU  
(A) Structure of doubly end-labeled polyP-MU. (B) Sequential digestion of doubly end-labeled polyP-MU with 
endopolyphosphatase and exopolyphosphatase. PolyP-MU was first incubated with or without 
endopolyphosphatase (250 nM Nudt2) for 80 min at 37 oC, after which varying concentrations of 
exopolyphosphatase (CIAP) were added to the indicated samples and the increase in fluorescence (AFU) was 
quantified over time. (C) Sequential digestion of doubly end-labeled polyP-MU, first, with or without 250 nM 
Nudt2 for 90 min at 37 oC, after which 5 U/mL CIAP was added to the indicated samples and fluorescence was 
quantified over time. (D) Simultaneous digestion of polyP-MU with the indicated concentrations of Nudt2 and 
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3.2       Introduction 
In both microbes and higher organisms, polyP is stored in a highly condensed state along with 
Ca2+ and other metal ions in acidic, electron-dense, membrane-bound organelles that have 
been given various names but are generally known as acidocalcisomes.1  Human platelets store 
abundant polyP in their dense granules,2 which strongly resemble acidocalcisomes. PolyP 
secreted from platelets is a potent modulator of blood clotting and inflammation,3 and polyP of 
the size released from platelets decays in human plasma and serum with a half-life of roughly 
90 minutes.3  We sought to identify the phosphatases responsible for degrading polyP in serum 
and were surprised to discover that almost all the polyP decay resulted from non-enzymatic 
hydrolysis mediated by the combination of millimolar concentrations of free Ca2+ and the 
slightly alkaline pH of serum.  This finding may explain why, throughout biology, polyP tends to 
be stored together with Ca2+ only in acidified subcellular compartments such as platelet dense 
granules, lysosomes, and fungal vacuoles.  This finding may also have relevance to the 




3.3       Results 
3.3.1:        POLYP DECAYS IN SERUM 
PolyP participates in an array of physiological processes.  PolyP secreted by activated human 
platelets, for example, is a potent modulator of blood clotting and inflammation.4  PolyP decays 
relatively quickly in plasma or serum, a characteristic which likely limits the molecule’s 
prothrombotic and proinflammatory actions in vivo.  Enzyme(s) responsible for polyP 
degradation in blood, though, have not been identified. Previous studies of polyP degradation 
have typically involved adding relatively large amounts of polyP to serum, then recovering the 
polyP and resolving it by gel electrophoresis [Figure 3.1].  This method is time-consuming and 
laborious.  Additionally, one potential complication of the method is that high concentrations of 
added polyP could overwhelm blood phosphatases, potentially dampening any measurable 
polyP-degrading activity.  To avoid this pitfall, we utilized a high-throughput, indirect ELISA-like 
assay for monitoring polyP degradation.5  The assay was previously developed in our lab and 
employs polyP bound 96-multiwell plates [Figure 3.2].  
 
We found that polyP decayed rapidly in this assay when incubated with human or bovine serum 
at 37 °C, such that 50% of the polyP signal was depleted in less than 1 hour [Figure 3.3].  This 
activity requires metal because addition of EDTA to serum abrogates polyP digestion, a finding 
consistent with the putative polyphosphatase being a metalloenzyme.   
3.3.2:        POLYP DEGRADATION IN SERUM IS METAL-DEPENDENT  
Likewise, depleting serum of divalent metal ions using Chelex 100 resin strongly attenuated the 
rate of polyP decay [Figure 3.4].  Adding divalent metal ions back to Chelex-treated serum, we 
found that the normal serum concentration of Ca2+  (2.5 mM) restored polyP degradation; 
adding back  Mg2+, Zn2+, Fe3+, or Cu2+ did not [Figure 3.4].  Adding high concentrations of metals 
(up to 5 mM) to Chelex-treated serum does not affect the rate of polyP decay for any metals 
other than calcium (data not shown).  It is possible, though, that some metals, once removed, 
are unable to re-populate phosphatases when added back to the metal-depleted serum (low 
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metal solubility or irreversible enzyme inactivation upon metal removal).  In any case, Ca2+ did 
restore activity.  Ca2+ is an unusual metal cofactor for phosphatases, however.  
3.3.3:        POLYP DEGRADATION RESISTS INACTIVATION BY PHOSPHATASE INHIBITORS  
Next, we tried to discriminate among the different types of phosphatases that could be 
degrading polyP by adding various genres of commercially-available phosphatase inhibitors to 
bovine serum (Table 3.1).  PolyP degradation, however, was unabated in the presence of the 
canonical phosphatase inhibitors [Figure 3.5]; the only compound that showed potency in 
inhibiting polyP decay was 10 mM EDTA, which strongly reduced the rate of polyP signal loss 
[Figure 3.3].  
3.3.4:        POLYP DEGRADATION IN SERUM IS HEAT-RESISTANT AND INCREASES WITH 
ALKALINITY 
Reviewing our previous results, we considered the possibility that the observed polyP 
degradation might occur through an enzyme-independent mechanism.  We therefore decided 
to boil the bovine serum and then measure phosphate degradation, as we expected high heat 
to denature potential serum phosphatases.  Bovine serum was boiled for 1 hour, cooled, and 
depleted of insolubles by centrifugation.  To our surprise, boiled serum supported nearly the 
same rate of polyP degradation as untreated serum, if not slightly accelerated [Figure 3.6, part 
A].   
 
We did not want to discount the possibility that polyP degradation were mediated by a heat-
resistant phosphatase, as some enzymes, such as RNAses, can re-fold after heating.  Heat-
resistant or not, enzymes have pH optima. For a given enzyme, plotting activity rate vs. pH 
should yield a bell-like curve, and the apex of that curve should be the pH optimum.  Given the 
nature of blood’s bicarbonate-based buffering system, boiling serum would cause a rise in 
serum pH (Table 3.2), and the rise in pH could explain why polyP degradation increased slightly 
upon boiling serum if polyP decay were caused by a heat-resistant alkaline phosphatase.  We 
next tested how the polyP-degrading activity of serum changed with pH.  As the pH rose, the 
rate of polyP degradation just continued to increase [Figure 3.6, part B].  We did not measure 
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the rate past pH = 10 as that is a supraphysiological pH and beyond the point at which our assay 
can distinguish polyP degradation (phosphoanhydride bond breakage) from hydrolysis of the 
biotin—polyP linkage (phosphoramidate linkage) connecting polyP to the plate wells in our 
assay [Figure 3.2].  We did not observe a bell-shaped curve for the phosphatase-like assay.  
Taken together, our findings impelled us to create a new hypothesis: PolyP degradation in 
serum might be directly metal-mediated, rather than indirectly through enzymatic catalysis.   
3.3.5:        METAL, ALONE, IS SUFFICIENT TO CAUSE POLYP HYDROLYSIS 
Previous work has shown that incubating polyP with calcium and certain other metal ions at 
high temperatures with high Ca:P ratios can cause polyP degradation.6  We wanted to know if 
metals alone were sufficient to cause polyP degradation under more-physiologic-like 
conditions.  To examine the role of Ca2+ and other divalent metal ions in catalyzing polyP decay, 
we repeated the microplate-based polyP degradation assay using physiologically relevant 
divalent metal ion concentrations in buffer (pH = 7.4) [Figure 3.7].  Ca2+, Zn2+ and Cu2+ all 
supported time-dependent polyP decay, with Ca2+ supporting approximately 50% loss of polyP 
signal in 1 hour.  Neither Mg2+ nor Fe3+ supported polyP degradation.   
 
Cu2+ and Zn2+ are intermediate/soft metals, which are known to have the ability to break 
phosphoramidate linkages, the linkages connecting polyP to the plates in our assays.  The polyP 
in this plate-based assay is covalently attached to biotin via a phosphoramidate linkage; 
therefore, we addressed the question of whether the metal ion-dependent decay of the 
observed polyP signal was caused by cleavage of the phosphoramidate linkage rather than 
hydrolysis of polyP, per se.  We incubated underivatized (un-linked), long-chain polyP in pH 7.4 
buffer with Cu2+ [Figure 3.8, part A] or Ca2+ [Figure 3.8, part B] for some hours, quenched the 
reactions with EDTA, and resolved the polyP by polyacrylamide gel electrophoresis. The results 
confirm a time-dependent shortening of polyP chains when polyP is incubated in solution with 





3.3.6:        ↑ METAL-MEDIATED POLYP DEGRADATION :: ↑ ALKALINITY 
Reviewing previous results, we saw that boiled bovine serum has roughly ½ the free Ca2+ that 
bovine serum has, yet retains comparable polyP-digesting ability.  Boiled bovine serum (pH ≈ 
7.8), however, is more alkaline than bovine serum (pH ≈ 7.6).  We wanted to test, therefore, 
whether or not pH might also affect rate of polyP degradation with calcium.   
 
We found that polyP decay in buffer was affected by buffer pH in a calcium-dependent manner; 
as the pH rose, polyP degradation increased in the presence of 1.25 mM Ca2+.  Adding EDTA to 
the buffer prevented polyP decay at all pHs.  It is important to note that polyP degradation in 
the presence of calcium at pH = 6.0 was very low [Figure 3.9], as it might be in an 
acidocalcisome. 
 
Taken together, these results support a previously undescribed mechanism of polyP 
degradation in serum by metal catalysis at or near physiological pH.  This finding is particularly 
interesting for clotting.  When platelets form a plug, they release polyP into the environment.  
It has been estimated that the microenvironment within a platelet plug is acidic.  If this is true, 
then a model can be proposed in which the half-life of procoagulant polyP needed at wound 
cites is prolonged by the acidic environment, but the polyP that moves with blood flow is 
degraded more quickly.  Alternatively, polyP may be taken up by cells or bind to other things.  A 
venue to explore would be how the degradation of polyP with metals is affected when polyP is 
bound to other molecules. 
3.3.7:        IN THE OCEAN 
In many organisms polyP is stored together with high concentrations of Ca2+ and other metals, 
some of which are also known to cause metal ion-facilitated polyP degradation in non-biological 
systems.6-8  Microorganisms, subject to their environment, take up various metals and many of 
these metals are sequestered with polyP in acidocalcisomes.  Recently, geologists found 
liberated marine diatomic acidocalcisomes present in calcium-phosphate sediments.9  
Diaz et al. determined that polyP from these acidocalcisomes formed up to 11% of dissolved 
phosphorus, but the polyP samples could only be extracted when sample water had been 
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deionized. Ocean pH and metal concentrations vary considerably with geographical location, 
local environment, and depth. Generally, though, oceanic pH lies between 7.5 and 8.5, and one 
of the more-abundant metal ions in the ocean is calcium (Table 3.3).10  Geologists believe that 
the vital calcium-phosphate nutrient sinks in the ocean are likely mineral deposits from 
deceased diatom polyphosphate stores,9, 11 but are unsure as to how calcium (mono)phosphate 
deposits might be nucleated from polyP. 
 
To see whether or not seawater had the capacity to degrade polyP, we utilized our polyP plate 
assay to observe polyP with seawater or autoclaved seawater.  Gulf coast seawater was filter-
sterilized prior to experiments. Sterilizing and autoclaving the seawater was unable to abrogate 
polyP degradation; metal chelator, however, slowed the activity [Figure 3.10].  
3.4       Discussion 
PolyP is an important molecule, both biologically and industrially, and its synthesis and 
degradation in the environment is of broad interest.  Using a high-throughput assay, we found 
that the bulk of ex vivo degradation of polyP (in serum)—contrary to long-standing 
hypothesis—was mediated not by endo- or exo(poly)phosphatases, but by free metal ions 
present in serum.  The observation that this metal-mediated degradation is pH-dependent, 
increasing with alkalinity, harmonizes with previous research showing that platelet-plug 
microenvironments—where it would be advantageous to perpetuate polyP’s half-life—are 
acidic.  The slowed calcium-mediated decay of polyP at low pH has broad biological 
implications, too. 
 
It has been observed that when microbial cells undergo alkaline stress, the cytosolic pH rises 
followed by the acidocalcisome pH.  Rise in acidocalcisome alkalinity is associated with polyP 
hydrolysis, calcium release, and subsequent cytosolic return to neutrality.  Examples of this 
happing were observed with cytosolic pH rises in Dunaliella salina (alga)12 and Trypanosoma 
cruzi.13  The reigning hypothesis for how cells regain livable pH is that the rise in alkalinity 
activates resident acidocalcisome-associated alkaline phosphatases; these phosphatases then 
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hydrolyze polyP to membrane-permeable acidic orthophosphates, restoring pH equilibrium.  In 
the two examples above, no specific phosphatases, however, were linked to the process. 
 
We propose an observational explanation as to why polyP, when stored with calcium and 
similar divalent metals, is contained within acidic compartments: to prevent constant polyP 
hydrolysis.  In mitochondria where polyP concentrations constantly fluctuate as part of 
metabolism, the pH is close to neutral.  Perhaps, when cells are alkalinized, the calcium or like 
metals present with polyP in acidocalcisomes directly causes the observed polyP hydrolysis and 
subsequent orthophosphate release from the organelles.r  Understanding how metal, especially 
calcium, and polyP interact may provide invaluable insight into processes of oceanic and bone 
mineral deposition or steer the future of antithrombotic drugs.  We believe these to be though-
provoking findings and submit that additional research should be explored that investigates 
whether or not alkalinity-induced acidocalcisome polyP dissolution is truly phosphatase-
mediated, or commenced through non-enzymatic means.  
  
                                                             
r Trimetapolyphosphate [Figure 1.1] is believed to be a product of central-chain polyP breakage.  Experimentally 
distinguishing this molecule from other polyphosphatase degradation products seems to be difficult, if not 
impossible, with current technologies.  Perhaps in the future, researchers might analyze closely phosphate-
containing products from cells that have undergone severe alkaline stress. 
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Figure   3.1:       PolyP Degradation Over Time in Human Serum 
200 µM polyP (478 mer) was incubated with donor serum for various increasing time periods. Following incubation 
in serum, polyP was extracted with 50 mM HEPES buffer (pH = 8.0)/10 mM EDTA/C6H5OH/CHCl3. Extracted samples 
were electrophoresed through 5% TBE-urea polyacrylamide gel and stained with 4',6-diamidino-2-phenylindole 
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Figure   3.2:       Schematic of PolyP Plate-based Assay 
Streptavidin is coated onto Corning high-affinity 96-well plates.  PolyP is biotinylated according to the methods 
previously described5 and bound to the streptavidin plates.  Wells were incubated for varying times with serum at 
37 °C, then washed with 1 M NaCl to remove any bound proteins or other materials.   Levels of remaining polyP 
were quantified using thrombin, which binds polyP avidly.  Thrombin cleaves the chromogenic substrate Sar-Pro-
Arg-pNA (p-nitroaniline), and pNA release is monitored spectrophotometrically at 405 nm.  Activity is measured in 
units of thrombin velocity (substrate cleaved/sec) and normalized to maximum thrombin velocity of wells in which 
polyP has undergone minimal hydrolysis. This assay employs very low levels of polyP, better reflecting the 
concentrations achievable in vivo following platelet activation (which can yield low µM concentrations of polyP in 






Figure   3.3:       PolyP Degradation in Serum 
PolyP degradation over time in human, bovine, or boiled bovine serum as measured in the plate-based assay 
system. Open symbols correspond to serum to which EDTA (10 mM) has been added.  All plots are taken as the 







Figure   3.4:       PolyP Degradation After Metal Removal & Reconstitution 
A, 2.5 mM CaCl2, 600 µM MgCl2, 50 µM FeCl3, 50 µM ZnCl2, or 50 µM CuCl2 were added to Chelexed serum prior to 
bovine serum incubation with polyP.  B, 2.5 mM of each of those metals were added.  All time courses were 
performed at 37 oC unless otherwise noted. All plots are taken as the mean of n ≥ 3 trials with error bars 








Figure   3.5:       PolyP Degradation in the Presence of Phosphatase Inhibitors  
Phosphatase inhibitors cocktails were added to bovine serum at suggested manufactured doses.  A list of individual 
cocktail components is available in (Table 3.1).  PolyP degradation over time in was measured in the plate-based 
assay system. All plots are taken as the mean of n ≥ 3 trials with error bars representing standard error of the 
mean.  * Bovine serum curve here is the same used in Figure 3.3 for comparison.  For this curve, n ≥ 6 trials, each 





Figure   3.6:       PolyP Degradation over Time in (Boiled) Bovine Serum 
A, PolyP degradation over time in bovine or boiled bovine serum as measured in the plate-based assay system. 
Open symbols correspond to serum to which EDTA (10 mM) has been added.  The boiled bovine serum plot is 
taken as the mean of n ≥ 3 trials with error bars representing standard error of the mean.  * Bovine serum curve 
here is the same used in Figure 3.3 for comparison.  For this curve, n ≥ 6 trials, each trial performed on different 
iteration.  Error bars represent standard error of the mean.  B, Time-course digestions of polyP in bovine serum at 
various pHs were measured. For each pH curve, an initial slope was calculated.  The raw initial-rate values were all 







Figure   3.7:       Metal-mediated PolyP Degradation over Time  
Physiologic concentrations of CaCl2 (2.5 mM), MgCl2 (600 µM), FeCl3 (50 µM), ZnCl2 (50 µM), or CuCl2 (50 µM) were 
added to 50 mM HEPES buffer (pH = 7.4) and incubated with the bound polyP.  Plots are taken as the mean of n ≥ 3 





Figure   3.8:       Ca- & Cu-mediated PolyP Degradation as Seen by Polyacrylamide Gel 
A & B, Time course of 40 µM polyphosphate (n ≥ 1,000 mer) incubated with 1.25 mM CaCl2 or 60 µM CuCl2 at pH 
8.0 for 0-6 h or 0-120 min, respectively. The (*) denotes polyP incubated for maximum time with no added metal. 
Reactions were stopped with EDTA. Samples were electrophoresed through a 15% TBE-Urea polyacrylamide gel 
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Figure   3.9:       PolyP Degradation with 1.25 mM Calcium vs Increasing pH  
2.5 mM CaCl2 was added to 50 mM MES 6.0, HEPES 7.0, HEPES 7.4, HEPES 8.0, CHES 9.0 and incubated with polyP. 
PolyP degradation was measured over time with these solutions by use of the plate-based assay system. PolyP 
decay in those same buffers lacking calcium or having with 5 mM EDTA are represented by open symbols with 
corresponding shapes and colors. Plots are taken as the mean of n ≥ 3 trials with error bars representing standard 







Figure   3.10:     PolyP Degradation in (Autoclaved) Seawater 
Degradation of polyP exposed to seawater (Gulf Coast; Sigma) was measured by plate-based assay.  The pHs of 
seawater and autoclaved seawater was consistently ~8.0.  Open symbols denote (autoclaved) seawater containing 





3.6       Tables 
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Data Table 3: ICP-OES measurement of the  
indicated elements in Gulf Coast seawater. 
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Table 3:         ICP Analysis of Seawater 
 Element Symbol Concentration  
     
 Sodium Na 480 mM  
 Magnesium Mg 36 mM  
 Calcium Ca 7 mM  
 Phosphorus P 16  µM  
 Copper Cu < 9  µM  
 Zinc Zn < 5  µM  
     
82 
 
3.7       References 
 
1. Docampo, R &  SN Moreno. Acidocalcisomes. Cell Calcium 50, 113-9 (2011). 
 
2. Ruiz, FA, CR Lea, E Oldfield &  R Docampo. Human Platelet Dense Granules Contain 
Polyphosphate and Are Similar to Acidocalcisomes of Bacteria and Unicellular 
Eukaryotes. J. Biol. Chem. 279, 44250-57 (2004). 
 
3. Smith, SA, NJ Mutch, D Baskar, P Rohloff, R Docampo &  JH Morrissey. Polyphosphate 
Modulates Blood Coagulation and Fibrinolysis. Proc. Natl Acad. Sci. 103, 903-8 (2006). 
 
4. Morrissey, JH, SH Choi &  SA Smith. Polyphosphate: An Ancient Molecule That Links 
Platelets, Coagulation, and Inflammation. Blood 119, 5972-9 (2012). 
 
5. Choi, SH, JN Collins, SA Smith, RL Davis-Harrison, CM Rienstra &  JH Morrissey. 
Phosphoramidate End Labeling of Inorganic Polyphosphates: Facile Manipulation of 
Polyphosphate for Investigating and Modulating Its Biological Activities. Biochemistry 
49, 9935-41 (2010). 
 
6. Momeni, A &  MJ Filiaggi. Comprehensive Study of the Chelation and Coacervation of 
Alkaline Earth Metals in the Presence of Sodium Polyphosphate Solution. Langmuir 30, 
5256-66 (2014). 
 
7. Thilo, E. Condensed Phosphates and Arsenates. Adv. Inorg. Chem. Radiochem. 4, 1-75 
(1962). 
 
8. Rulliere, C, L Perenes, D Senocq, A Dodi &  S Marchesseau. Heat Treatment Effect on 
Polyphosphate Chain Length in Aqueous and Calcium Solutions. Food Chem. 134, 712-16 
(2012). 
 
9. Diaz, J, E Ingall, C Benitez-Nelson, D Paterson, MD de Jonge, I McNulty &  JA Brandes. 
Marine Polyphosphate: A Key Player in Geologic Phosphorus Sequestration. Science 320, 
652-5 (2008). 
 
10. Vanderstappen, M &  R Van Grieken. Trace Metal Analysis of Sediments and Particulate 
Matter in Sea Water by Energy-Dispersive X-Ray Fluorescence. Analytical and 
Bioanalytical Chemistry, 25-30 (1976). 
 
11. Björkman, KM. Polyphosphate Goes from Pedestrian to Prominent in the Marine P-




12. Pick, U, M Bental, E Chitlaru &  M Weiss. Polyphosphate-Hydrolysis – a Protective 
Mechanism against Alkaline Stress? FEBS Lett. 274, 15-8 (1990). 
 
13. Rohloff, P &  R Docampo. Ammonium Production During Hypo-Osmotic Stress Leads to 
Alkalinization of Acidocalcisomes and Cytosolic Acidification in Trypanosoma Cruzi. Mol. 
Biochem. Parasitol. 150, 249-55 (2006). 
 
14. Smith, SA &  JH Morrissey. Sensitive Fluorescence Detection of Polyphosphate in 





APPENDIX A:       Β(1,4) SYNTHASES AND SCCHS2 
A.1       Introduction 
A.1.1:       CHITIN 
Chitin is a homopolymer of β(14)-linked GlcNAc sugars.  The molecule is a key structural 
component of fungal cell walls and arthropod exoskeletons (the one, in fact, that causes 
misfortunate bugs to crunch).  After cellulose, which is structurally-related to chitin, chitin is the 
most abundant biological macromolecule on Earth.  Despite chitin’s ubiquity in the 
environment, however, the mechanism of β(14)-linked polymer synthesis is not well-
understood.1   
A.1.2:       Β(1,4) POLYSACCHARIDE SYNTHASES & Β(1,4) POLYSACCHARIDE SYNTHESIS 
What is known is that the polymer is synthesized by processive, inverting enzymes of the 
Glycosyltransferase (GT) Family 2, whose members also include cellulose synthases and class I 
hyaluronic acid synthases.2-6  Organisms which produce chitin express chitin synthases (CS), and 
CSs catalyze the reaction  
 
n (UDP-α-GlcNAc)+ GlcNAc—(GlcNAc)i  n UDP + GlcNAc—(GlcNAc)(i + n). 
 
Biological UDP-GlcNAc has an α-configured anomeric carbon.  During the reaction, the non-
reducing-end 4-hydroxyl of the first GlcNAc is used in a nucleophilic attack upon a second UDP-
attached GlcNAc.  Addition of the second UDP-GlcNAc to the preceding residue in the chitin 
chain switches the anomeric carbon configuration from alpha to beta.  Because CSs seemingly 
“flip” the anomeric carbon configuration, chitin synthases are called inverting enzymes.  
Cellulose synthases, too, are also inverting enzymes.  Multiple-sequence alignments have 
helped to identify conserved motifs in known chitin synthases, 7, 8 and hydropathy analyses 
have prompted transmembrane-topology models for the inverting enzymes.5  The synthases 
have a large cytoplasmic domain where the catalytic site is located; the other transmembrane 
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segments may agglomerate themselves, forming a pore through which the chitin chains are 
extruded past the plasma membrane.   
 
Forming β(14) linkages between successive sugars presents a steric challenge: each 
successive residue is rotated nearly one hundred eighty degrees relative to its neighbor.  This 
fact necessitates that each new monosaccharide must be transferred from its sugar donor (e.g. 
UDP-GlcNAc for CSs, UDP-Glucose for cellulose synthases) to a nucleophilic acceptor’s hydroxyl 
group that, somehow, alternates between two positions.  There have been various models 
proposed to explain the synthetic problem.  In one scenario monosaccharides are transferred 
one-at-a-time by a single synthase.  Another description holds that synthases like CS are 
homodimers having two catalytic sites which operate alternately.  A third model is that each 
enzyme has two UDP-Sugar binding/catalysis sites, thus elongating a chain with two 
simultaneous monosaccharides (Reviewed1).  In January of 2013, J Morgan et al. published the 
crystal structure of a bacterial cellulose synthase that extends the polysaccharide one-glucose-
at-a-time.9  Many plants have multiple cellulose synthases, and most fungi have multiple CSs 
which are active in different cellular locations at distinct times during cell growth and 
division.10-12   
A.1.3:       CSS IN SACCHAROMYCES CEREVISIAE 
Saccharomyces cerevisiae has three CSs: ScChs1, ScChs2, and ScChs3.  These three proteins 
contribute differently to overall yeast chitin synthesis in vivo, and the enzymes’ in vitro 
properties are distinctive as well. 13-15   
A.1.3.1       ScChs1 
ScChs1 emerges at the yeast division septum and is thought to repair chitinase-induced cell wall 
damage that occurs when mother cell and bud separate. 16  ScChs1 makes little detectable 
chitin in vivo, but the enzyme’s in vitro trypsin-stimulated activity is much higher than that of 
the other two CSs.  Strangely, this in vitro activity is latent, and researchers have been unable to 
find conditions under which the activity is increased to that extend without exposing the 
enzyme to pre-treatment with trypsin. 13, 15   
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A.1.3.2       ScChs3 
Making over ninety percent of the chitin in replicating yeast cells, ScChs3 deposits chitin in a 
ring at the base of the yeast bud, and the chitin accumulation at the bud scar persists even after 
cell separation. 10, 15  Unlike ScChs1 activity, ScChs3 activity is inhibited by trypsin pre-
treatment. 15  Yeast ScChs1, ScChs3 double-knockouts (ΔCHS1 ΔCHS3) are viable. 
 
A.1.3.3       ScChs2 
Chs2 is the final major CS in Saccharomyces cerevisiae.  In vivo, ScChs2 localizes to the yeast bud 
neck region to make the primary septum between the two buds of a cytokinesing cell.10  The 
protein appears only very shortly during cytokinesis and then is degraded.  In vitro, ScChs2 can 
be stimulated by trypsin to synthesize two-to-four-fold more chitin than ScChs2 that without 
trypsin treatment.7, 14  What triggers ScChs2 chitin synthesis in vivo, though, is poorly 
understood.  Genetic and cytological analyses, as well as co-localization studies, reveal that the 
proteins Dbf2 (kinase), Inn1, Hof1, and Cyk3 are involved mediating ScChs2 activity in the neck 
region. 17-19   
A.1.4:       A UNIQUE SCCHS2 STRAIN ARRIVES AT UIUC 
The Erfei Bi lab (U Penn) studies cell polarity and morphogenesis in S. cerevisiae.  Of particular 
interest to the group is understanding what mechanisms control the time-dependent 
localization to and disappearance of Chs2 at yeast cell plasmamembrane.20  The Bi lab had 
created yeast strains in which they had mutated what appeared to be important Chs2 residues 
for chitin deposition.  They believed the mutations affected Chs2 activity by preventing Chs2 
phosphorylation, and thus, proper localization to crucial sites.  To rule out the possibility that 
the mutations were directly depressing the enzyme’s catalytic activity, they asked us to 
measure chitin synthesis in the various mutants.21  What was most exciting about strains the Bi 
lab sent was that the ChS2 expression and activity in the (ΔCHS1 ΔCHS3)’s was high a priori, so 
membrane—trypsin incubation prior to assaying chitin synthesis was not needed.  With these 
and few slightly-modified strains, we were able to explore the role of GlcNAc and other 
monosaccharides or disaccharides in priming chitin chain synthesis.   
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B.2        Introduction 
B.2.1:       POLYSACCHARIDES 
Long chains of sugar moieties linked to one another through glyosidic bonds are called 
polysaccharides, and these polymers are ubiquitous, appearing throughout biology and in 
medicinal and industrial applications.  One important polysaccharide is chitin, a homopolymer 
of β-(14)-linked N-acetylglucosamine (GlcNAc) sugars.  Chitin is a key structural component of 
arthropod exoskeletons and fungal cell walls and a polymer often utilized for experimental drug 
delivery.  The polysaccharide is synthesized by processive enzymes of the Glycosyltransferase 
(GT) Family 2, whose members include cellulose synthases and class I hyaluronic acid 
synthases.4-8  Cellulose—an important component of paper—is structurally related to chitin, 
and together, chitin and cellulose are the most abundant biological macromolecules on Earth 
[Figure B.1, part A].u   
 
Despite the polymers’ pervasiveness in the environment, however, the mechanism of 
β-(14)-linked polymer synthesis is not well-understood.9  Studying β-(14)-polysaccharide-
synthesizing enzymes is wrought with technical difficulties:  First, most of the enzymes are 
multi-spanning membrane proteins, which can be as difficult to express as purify.  Adding to the 
complexity of such experimental systems is that many organisms that synthesize chitin and/or 
cellulose possess multiple, distinct chitin and/or cellulose synthases and resolving the individual 
enzymes’ contributions is challenging.  Even if one is able to isolate the activity of a single 
enzyme, at certain lengths, both chitin and cellulose become highly water insoluble, making 
product analysis less amenable to standard analysis methods. 
 
Despite technical obstacles, the field has made strides in understanding β(14) polysaccharide 
synthesis.  In 2013 the first cellulose synthase crystal structure was generated10 and already has 
provided valuable insight into the mechanism of β(14) polysaccharide synthesis.10-12  What is 
particularly interesting about the β(14) polysaccharides is the intrinsic nature of the 
glycosidic bonds.  Each sugar residue is flipped 180o with respect to its adjoining neighbors, and 
                                                             
u Dr. J. Sweedler vehemently opines that lignin is probably the most abundant natural polymer. 
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a few models have been proposed to explain how an enzyme active site could simultaneously 
accommodate two disparate geometries.9  Two equally important questions about β(14) 
polysaccharide synthesis are how growing chains are elongated (processivity of the enzymes) 
and how the polysaccharide chains are initiated, or primed, a priori. 
B.2.2:       THE “GLCNAC EFFECT” 
The accepted typical reaction of chitin synthases is the following: 
n (UDP-α-GlcNAc)+ GlcNAc—(GlcNAc)i  n UDP + GlcNAc—(GlcNAc)(i + n). 
Where (GlcNAc)i is the growing chitin chain elongated by chitin synthase. 
 
Over the years, investigators have noticed that many chitin synthases supplied with free GlcNAc 
produce three-to-forty-fold more insoluble chitin than membranes incubated without free 
GlcNAc.1, 2, 13-19  Free GlcNAc is not required in all cases, however, and the concentration of 
GlcNAc added to elicit maximum effect can be up to 40 mM, which most investigators think 
seems supraphysiologic.  In cases where GlcNAc is not necessary for chitin synthesis but greatly 
stimulates it, researchers hypothesize the free sugar may be acting as a primer19 for chitin 
chains or molecular activator16, 20 of the chitin synthase.  How or where chitin synthases might 
encounter in vivo [GlcNAc]s high enough to elicit the profound “GlcNac effect” remains a 
mystery.  Some groups think free GlcNAc may actually mimic a true, so-far-unidentified 
endogenous primer of chitin synthesis.  
B.2.3:       SACCHAROMYCES CEREVISIAE CHS2 AND GLCNAC ANALOGUES 
In this work we sought to add valuable insight into the mechanisms of β(14) chain elongation 
and the GlcNAc effect on chitin synthesis.  Using a Chitin-Synthase-II-(Chs2)-overexpressing, 
ΔCHS1ΔCHS3 Saccharomyces cerevisiae strain (YO1535)21, we isolated the activity of a single 
eukaryotic chitin synthase.  We found that our preparations of ScChs2 not only produced long-
chain insoluble chitin, but also soluble short-chain chitin, and we used these soluble products to 
investigate the effects of various mono- and disaccharide primers on chitin synthesis.  Our 
results were that in vitro chitooligosaccharide formation is strongly dependent upon the 
inclusion of free GlcNAc.  Surprisingly, select 2-acylamido analogues of GlcNAc also elicit robust 
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Chs2 activity.  Using thin layer chromatography and mass spectroscopy analysis, we observe 
that Chs2 not only can transfer a single GlcNAc from UDP-GlcNAc to 2-acylamido- analogues of 
GlcNAc, but also can extend the resulting disaccharide with subsequent GlcNAc residues.  We 
cannot rule out the possibility that GlcNAc is also a molecular activator of Chs2, but the 
incorporation of GlcNAc and its analogues into chitin chains is consistent with GlcNAc serving as 
or mimicking the endogenous primer of chitin synthesis.  Our findings may have significance for 
broader applications.  We believe the findings here are relevant to current pesticide and anti-
fungal development and could provide the underpinnings for new exploration in renewable 
energy research centered on cellulose synthases. 
 
B.3        Results 
B.3.1:       YO1535, A MODEL SYSTEM FOR STUDYING CHITIN SYNTHESIS 
Before we could explore free GlcNAc’s effect on a single chitin synthase (CS), we needed to 
isolate a single CS.  For this singular enzyme, we chose Chs2 from Saccharomyces cerevisiae.  
Like many other chitin-producing organisms, S. cerevisiae has multiple CS and each CS 
possesses distinct cellular and kinetic properties22-24 [Figure B.2].  Unlike many other organisms, 
however, S. cerevisiae can survive a knockout of two of its three CS genes.  By using a 
ΔCHS1ΔCHS3 background strain for experiments, we limit yeast chitin production to that from 
Chs2 only.  Chs2 is a membrane protein and is thought to be a zymogen.  Researchers find that 
chromosomally-encoded Chs2 chitin production is barely detectible1, 15 unless one first 
incubates Chs2-containing membranes with trypsin.  In 2012, however, Oh et al. created a 
ΔCHS1ΔCHS3 strain in which CHS2 was overexpressed from a high-copy, galactose-inducible 
plasmid (strain YO1535),21 and membranes from YO1535 have robust Chs2 activity without 
prior protease treatment [Figure B.3, part A].   
 
The typical chitin synthase (CS) assay is run at 30 oC and includes the following components: 
membrane fractions (i.e. partially purified enzyme preparations), buffer, radioactive CS 
substrate (UDP-*GlcNAc), divalent metal ions, and (often) free GlcNAc.  One halts the reaction 
with acid or EDTA addition or high-heat incubation and collects the enzyme product (insoluble 
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chitin) atop a filter through vacuum-mediated filter exclusion.  The dried material is quantified 
by scintillation count.1, 8, 23, 25  UDP-GlcNAc is CS’s substrate and without it no product is 
produced.  Canonically, the rate at which a reaction product forms mirrors the rate at which a 
reactant is used.  We assayed YO1535 membranes in the absence of GlcNAc, comparing chitin 
formation to UDP-GlcNAc decay.  What we observed was that the chitin production and 
UDP-GlcNAc consumption rates were disparate, the rate of UDP-GlcNAc consumption 
exceeding that of chitin deposition [Figure B.3, part B].  It is known that a fraction of 
UDP-GlcNAc is used by S. cerevisiae to modify glycolipids (e.g. phosphatidylinositol for GPI 
anchors, dolichol phosphates for N-linked glycans).  We considered that another possible 
contributory factor to the differing rates might be Chs2 synthesis of soluble, short-chain 
chitooligosaccharides lost through filter exclusion.  If Chs2 were to make appreciable amounts 
of chitooligosaccharides (as demonstrated in a few other CSs2, 19, 26, 27) the finding may lend 
insight into the processively of CSs, whether the chitooligosaccharides were long-chain 
intermediates or reaction byproducts.  
B.3.2:       SCCHS2-CONTAINING MEMBRANES MAKE CHITIOOLIGOSACCHARIDES 
To test the hypothesis that Chs2 might use UDP-GlcNAc to make chitooligosaccharides, we 
performed the typical CS assay but modified our collection procedure for the ChS2 product.  As 
before, Chs2-overexpressing membranes from the CHS1ΔCHS3Δ cells were incubated with 
UDP-[14C]GlcNAc in a time course.  Reactions were halted by briefly boiling the samples and the 
resulting mixtures were centrifuged.  The supernatant liquid was collected, subjected to Dowex 
resin for removing unreacted UDP-GlcNAc, and blotted onto a Silica gel 60 Thin Layer 
Chromatography (TLC) plate for development.28  Just as the amount of insoluble chitin had 
increased with time [Figure B.3, part B], so, too, had the appearance of soluble 14C-containing 
products [Figure B.4].  The products appeared to form a ladder much like the chitinous ladder 
Kamst et al. 1999 observed while characterizing the rhizobial chitinase Nod C, a chitinase that 
primarily produces chitooligosaccharides.28  In their study the authors found that the shortest 
chitooligosaccharides migrated the furthest from the origin and thought that the largest bands 




To assess whether the bands we observed might be chitooligosaccharides or another 
metabolite, we subjected the aqueous-phase products to chitinase digestion.  If the ladder 
were made of chitin, we expected the putative large chitin bands to disappear.  Ch2 assays 
were performed without GlcNAc as described in materials and methods for a time period of 
15 minutes.  This time, reaction mixtures were phase partitioned into aqueous-soluble, organic-
soluble, and aqueous/organic-insoluble materials (according to an adaptation of the procedure 
of Bligh & Dyer).29  Unreacted UDP-GlcNAc was removed from the aqueous-soluble material.  
Then, the samples were incubated either with chitinase buffer or chitinase and buffer.  The 
digestion mixtures and lipid fractionated material were submitted to separation by TLC, and 
radiolabeled material on the TLC plate was detected by phosphorimaging.  Upon incubation 
with chitinase, the laddered material collapses into a single detectible band, presumably 
chitinase-hydrolyzed free [14C]GlcNAc [Figure B.5, part A].   
 
Though our results [Figures B.4 & B.5, part A] were consistent with the Chs2 enzyme making 
soluble chitooligosaccharides (COs), we could not exclude the possibility that the COs we 
detected were actually products of long chain chitin digestion rather than of Chs2 synthesis.  
Utilizing the cloning method of Baudin et al. (1993), we knocked out the yeast chitinase gene 
CTS1 in a CHS1ΔCHS3Δ background strain, replacing the gene with the LEU2 gene.  We then 
transformed the CTS1ΔCHS1ΔCHS3Δ strain with the CHS2-overexpression plasmid.  (See 
Materials and Methods.)  As Kang et al. (1984) astutely highlighted, definitively distinguishing 
chitinase-digestion-caused CO formation from CO synthesis may be difficult, if possible.  Also, 
as positied by the same group, CSs themselves may possess inherent chitinase activity.26  
Additionally, researchers have noted that certain glycosyltransferases tasked with crosslinking 
cell wall polysaccharides can behave in vitro as nonprocessive polysaccharide-cleaving enzymes.  
If enzymatic cleavage of long-chain chitin, rather than short-chain chitin synthesis, accounted 
for the source of COs, then one could imagine another possible explanation of the GlcNAc 





B.3.3:       GLCNAC STRONGLY STIMULATES BOTH SHORT- AND LONG-CHAIN CHITIN SYNTHESIS 
We hypothesized that if the COs are chitinase degradation products and GlcNAc increases long-
chain chitin synthesis by inhibiting chitinases, then adding GlcNAc to Chs2 assays should 
increase insoluble chitin counts while decreasing CO counts.  To test this hypothesis, we 
incubated Chs2-overexpressing membranes for 15 minutes with increasing concentrations of 
UDP-GlcNAc; and for these incubations, we either included or witheld mM free GlcNAc to/from 
the assay.  Products were separated by phase in the method of Bligh and Dyer and quantified.  
First, we saw that adding free GlcNAc to reaction mixtures caused an increase in the rate at 
which UDP-GlcNAc was consumed by membranes [Figure B.6, part A].  Second, we found that 
GlcNAc not only stimulated insoluble chitin production, but CO synthesis also [Figure B.6, part 
B].  There was only a slight increase in detected radioactivity in organic-soluble materials 
(GlcNAc-modified lipids).  Upon addition of GlcNAc, CO synthesis predominates at low substrate 
concentrations.  Interestingly, in lanes containing “+ GlcNAc” products there seemed to be a 
dominant black band corresponding to a low molecular weight product we thought might be 
the disaccharide GlcNac2 [Figure B.6, part B].  Together, this evidence led us to hypothesize that 
GlcNAc may be acting an allosteric regulator of Chs2 or as a synthesis-priming molecule for it. 
B.3.4:       SCCHS2 INCORPORATES GLCNAC AND GLCNAC ANALOGUES INTO CHITIN STRANDS  
To test whether or not Chs2 might elongate free GlcNAc, we decided to see whether or not we 
could stimulate CO synthesis using GlcNAc analogues.  If Chs2 elongates non-GlcNAc sugars, we 
would expect to see a chromatographic shift in the chitin product ladders Chs2 makes from 
those sugars.  To do this, we added GlcNAc, GlcNAc2, GlcNAc3, GlcN, GalNAc, ManNAc, and Glc 
to CHS2-overexpressing membranes, collected aqueous fractions, subjected the fractions to TLC 
separation, and visualized the resultant radioactive bands by phosphorimaging the TLC plate.  
The same plate was then sprayed with a chemical reagent to reveal the presence of all 
carbohydrates [Figure B.7, part A].  GlcNAc2 stimulated formation a product ladder similar to 
that of GlcNAc.  A striking difference between the product ladders of GlcNAc and GlcNAc2, 
though, is that the darkest band in the GlcNAc2 lane has a higher molecular weight than the 
darkest band in the GlcNAc lane.  Though not conclusive, this finding would be consistent with 
Chs2 using both GlcNAc and GlcNAc2 as acceptors.  There appeared to be no difference among 
 98 
 
the bands in the GlcNAc3-added and no-GlcNAc-added lanes.  It may be that Chs2 intrinsically is 
unable to elongate the trisaccharide, or, as intimated by the elongated stain in the TLC-sprayed 
figure [Figure B.7, part A], GlcNAc3 ‘s poor solubility may have prevented Chs2 from elongating 
the trisaccharide.   GlcN, GalNAc, and ManNAc were without detectible effect.  A doublet band 
appeared in the Glc lane, the band situated between where GlcNAc2 and GlcNAc3 would run.  
Glc has been known to stimulate long-chain chitin synthesis in other CSs,13, 16 and a possible 
identity for the new material might be a GlcNAc—Glc disaccharide.   
 
To explore this possibility further, we needed to use GlcNAc analogues with mobilities that 
were considerably distinct from that of GlcNAc.  If Chs2 were able to elongate any such 
analogues, then we should see a significant shift in all bands of the product ladder compared to 
the ladder formed by GlcNAc.  With this aim in mind, we synthesized three glucosamine-
substituted GlcNAc analogues: N-propanoyl- (GlcNPr), N-butanoyl- (GlcNBu), and N-
glycolylglucosamine (GlcNGc).30  Standard Chs2 assays with 2 mM UDP-GlcNAc were performed, 
and we looked for evidence of CO synthesis with these analogues.  All three GlcNAc analogues, 
as well as GlcNAc2, seemed to stimulate CO synthesis [Figure B.7, part B]; furthermore, CO 
product ladders from membranes incubated with GlcNPr, GlcNBu, and GlcNGc had 
systematically shifted chromatographic mobilities in a manner consistent with the possibility 
that the analogues had been incorporated into COs [Figure B.7, part B].  Interestingly, GlcNPr 
and GlcNBu more greatly stimulated long polymer synthesis than GlcNAc did over a range of 
substrate concentrations.  
 
In order to try to confirm that the GlcNAc analogues indeed had been incorporated into 
chitinous products, we used MALDI analysis to identify Dowex-cleaned, aqueous soluble 
material from Chs2 assays with GlcNPr, GlcNBu, and GlcNGc.  Masses from the product material 
were consistent with those expected for sodium adduct [M + Na]+ ions of di- and trisaccharides 
of each GlcNAc analogue [Figure B.8].  Because the GlcNAc analogues had been incorporated 




B.4       Discussion 
By focusing on the soluble products of the reaction carried out by yeast Chs2, we have garnered 
new insights into the synthetic capabilities of CSs.  Our major findings are that (i) in vitro 
formation of COs by Chs2 is strongly dependent on free GlcNAc and the 2-acylamido-GlcNAc 
analogues tested; (ii) Chs2 transfers GlcNAc from UDP-GlcNAc to the GlcNAc analogues GlcNPr, 
GlcNBu, and GlcNGc; and (iii) Chs2 can transfer single GlcNAc residues yielding a disaccharide as 
major product. We are the first to show direct inclusion of a low molecular weight primers into 
growing chitin chains from a eukaryotic organism.   
 
Because GlcNPr, GlcNBu, and GlcNGc all serve as GlcNAc acceptors, we believe that at least part 
of the stimulatory effect of free GlcNAc on chitin synthesis is its acting as an acceptor for 
GlcNAc transfer.  Because GlcNAc2, GlcNPr, GlcNBu, and GlcNGc did not stimulate the formation 
of unmodified GlcNAc2 or GlcNAc3, we find it unlikely that these analogues (and possibly 
GlcNAc) serve as generic allosteric CO synthesis activators.  Some primers and substrates do, 
however, act as allosteric enzyme activators when present in the enzyme active site.  We 
cannot rule out, therefore, the possibility that GlcNAc is an allosteric activator of CO and 
insoluble chitin synthesis as well as a primer of it.  In our experiment looking at insoluble chitin 
synthesis with GlcNAc and varying [UDP-GlcNAc]s [Figure B.9], we noticed a slight sigmoidal 
curve.  This has been noticed by other labs, too.31  It may be that there is some sort of 
cooperativity or perhaps that some of the insoluble product of a certain length is lost through 
the filtering process.  Wev found that our adding glycerol to membrane preparations causes 
stimulation of Chs2, so that when GlcNac is withheld from assays, Chs2 membranes do not 
actually produce CO bands detectible by TLC [Figure B.9].  Glycerol stimulation of CS has been 
seen previously.13  When experiments are repeated, the sigmoidal curve still appears.   
 
It is not clear how GlcNAc-stimulated CO formation, the primer function of GlcNAc and its 
analogues, and GlcNAc-dependent stimulation of insoluble chitin synthesis are all related to the 
                                                             
v J. Gyore & PABO 
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mechanism of chitin formation by Chs2 in vitro. We consider possible explanations in the 
context of processive and distributive mechanisms for polysaccharide polymerization. 
 
The current model for the polymerization mechanism of glycosyltransferase family 2 
polysaccharide synthases, which is based on the structure of Rhodobacter cellulose synthase 
BcsA, is for chain extension one sugar residue at a time with concomitant extrusion of the 
growing glycan chain through a channel created by the transmembrane domains of the 
enzyme.10  In the context of this processive model, the COs formed by Chs2 in the presence of 
GlcNAc may be generated as a result of premature chain termination,26 but alternatively, they 
may result from aberrant initiation in vitro. Thus, GlcNAc and its analogues may intrude into the 
catalytic site, compete with an enzyme-bound, nascent chitin chain, and prime CO formation, 
whereupon some COs dissociate from the enzyme, but others remain bound and are elongated, 
explaining the stimulatory effect of GlcNAc and its analogues on synthesis of both COs and 
insoluble chitin. This speculative explanation accommodates preliminary observations that the 
COs formed in pulse-chase experiments appeared stablew,26 and leads to the prediction that 
average length of the in vitro Chs2 products formed in the presence of GlcNAc will be shorter 
than the product made in the absence of GlcNAc. 
 
It is formally possible that Chs2 uses a distributive polymerization mechanism, in which the 
synthase disengages from its elongated product after every round of catalysis, then 
reassociates with a new acceptor and donor substrates for transfer of another monomer.32  In 
this case, free GlcNAc would also be expected to enhance CO formation. 
 
That GlcNAc stimulates CO and chitin synthesis in vitro is consistent with GlcNAc being the 
normal primer of de novo chitin synthesis, but we cannot exclude the possibility that in vitro, 
GlcNAc and its 2-acylamido analogues mimic an endogenous primer that is distinct from 
GlcNAc. If the latter is the case, this primer moiety should be present on the COs made in the 
absence of free GlcNAc, but because the amounts of COs made in these incubations are too 
                                                             
w PAB Orlean, unpublished results. 
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small for analysis, it is not yet possible to determine whether these COs bear a terminal moiety 
different from GlcNAc. If free GlcNAc is indeed the in vivo primer, it would have to be generated 
by dephosphorylation of GlcNAc phosphates formed during UDP-GlcNAc synthesis or following 
hydrolysis of UDP-GlcNAc because the free sugar is not an intermediate in UDP-GlcNAc 
synthesis.33 
 
Our findings were made with S. cerevisiae Chs2 and with membranes that had not been 
pretreated with protease, but we propose they apply to other CSs as well. However, CSs may 
differ in their relative abilities to use GlcNAc and its 2-acylamido analogues as acceptors, as well 
as in the extent to which these compounds stimulate CO formation in vitro. Partial proteolysis 
may also impact the response of CSs to GlcNAc and its 2-acylamido analogues, as well as the 
size range of CS products. 
 
Our results have implications for the mechanism of other β-linked polysaccharide synthases of 
glycosyltransferase family 2.  Our findings that Chs2 can elongate 2-acylamido-GlcNAc 
analogues indicate that Chs2 must be able to tolerate somewhat-bulky acetyl groups on the 2’ 
carbon of glucosamine.  Horsch et al. (1996)16 used Mucor rouxii CS to concluded that the 
aminoglucopyranose skeleton, acylated amino group, and a single-bonded oxo at the 1’ were 
necessary for a sugar to act as a chitin synthesis effector.  Large groups at the C-6 position may 
also be tolerated because addition of 6-O-dansyl-GlcNAc to regenerating Candida albicans 
spheroplasts led to incorporation of this GlcNAc analogue into alkali-insoluble material,34 
although it is not certain that a CS was directly involved. 
 
The finding that Chs2 can transfer a single GlcNAc from UDP-GlcNAc is direct support for the 
conclusion drawn from the structure-based model for the bacterial cellulose synthase BcsA that 
spatial restrictions in the substrate binding site would allow cellulose extension by one, rather 
than two glucoses at a time.10  Kamst et al. (1999) Biochem.28 also concluded that the bacterial 
chitin synthase homologue NodC sequentially transferred monosaccharides during CO 
synthesis. The finding that the 2-acetylamido position can tolerate modifications raises the 
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possibility of introducing reactive groups at this position to tether acceptor residues. Further, 
CSs may prove able to use the UDP-derivatives of 2-acylamido-GlcNAc analogues as substrates 
and generate chitin derivatives whose 2-acylamido side chains bear groups that confer novel 
properties.  In addition to being interesting, the findings here are relevant to current pesticide 
and anti-fungal development and could provide the underpinnings for new exploration in 





B.5        Experimental Procedures 
B.5.1:       STRAINS 
 
B.5.1.1:       Chs2-overexpressing strains 
S. cerevisiae strains YO1111 (chs1Δchs3Δ), YO1528 (chs1Δchs3Δ pRS314), and YO1535 
(chs1Δchs3Δ pYO201) were described previously.21  
B.5.1.2:       ΔCTS1 strain 
The CTS1 gene in YO1535 was deleted and replaced with the yeast LEU2 genex.35  The sequence 
of the forward oligonucleotide primer used to amplify a DNA fragment consisting of LEU2 and 
nucleotides immediately upstream and downstream of the CTS1 coding sequence was  
5’-ACATTGAAATTCTAATTTAAATATAAAATAATTAATAATAGAATGCGTTTCGGTGATGAC-3’ and the 
sequence of the reverse primer was 5’- 
AAAAAAAATATTCGGACTCTATGAATCAATCTCTAATAACTTTACTTACGCATCTGTGCG -3’y.  
Elimination of Cts1 activity was verified by testing culture supernatants of candidate cts1::LEU2 
mutants for release of 4-methylumbelliferone from 4-methylumbelliferyl-b-D-N,N’,N’’-
triacetylchitotrioside (Sigma).z35 For induction of CHS2 expression, strains were pre-grown for 
24 hours at 30 °C in synthetic complete (SC) medium lacking tryptophan containing 2% (w/v) 
glucose. Cells were then collected by centrifugation and resuspended in 250 mL SC medium 
minus tryptophan containing 2% (w/v) galactose and 1% (w/v) raffinose. Induction of CHS2 
expression was performed for 18-21 hours at 25 °C. 
B.5.2:       MEMBRANE (ENZYME) PREPARATION 
Mixed membrane fractions were prepared as described in Y Oh et al. (2012) Mol. Biol. Cell,21 
except that, where noted, glycerol was omitted from the final buffer (30 mM Tris-HCl pH 7.5) in 
                                                             
x
 This strain was made by CFFH with assistance from Mr. Steve Kim. 
y There is an error in the sequence listed in the original manuscript. The sequence written above is that of the 
reverse primer that CFFH created, had approved by PABO, and submitted to Integrated DNA Technologies through 
the lab account (2012-04-06).  
z Performed by PABO. 
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which membranes were homogenized. Membranes were frozen at -80 °C and thawed just 
before use. 
B.5.3:       ASSAYS FOR CHITIN-OLIGOSACCHARIDE AND CHITIN-POLYSACCHARIDE SYNTHESIS 
Incubation mixtures for assay of formation of 10% trichloroacetic acid-insoluble, [14C]GlcNAc-
labeled polymer contained, in a final volume of 50 mL, 2 mM UDP-GlcNAc, 50 nCi UDP-
[14C]GlcNAc (sp. act.: 300 mCi/mmol, American Radiolabeled Chemicals, St. Louis, MO, USA), 
2.5 mM cobalt acetate, and, when included, 32 mM GlcNAc, N,N’-diacetylchitobiose, or 
N,N’,N”-triacetylchitotriose (from Sigma).21  Reactions were started by addition of 20 mL of 
membranes, and mixtures were incubated at 30 °C, typically for 30 min. Incubation mixtures for 
formation of COs contained 125 or 250 nCi UDP-[14C]GlcNAc, corresponding to final UDP-
GlcNAc concentrations of 0.046 mM or 0.092 mM respectively. In some assays of CO synthesis, 
unlabeled UDP-GlcNAc (from Sigma) was added to give higher final UDP-GlcNAc concentrations. 
To stop reactions, 375 mL chloroform/methanol 1:2 (v/v) was added to incubation tubes.29 
B.5.4:       CHITOOLIGOSACCHARIDE EXTRACTION & PURIFICATION FOR ANALYSIS BY TLC 
Reaction mixtures were then fractionated according to an adaptation of the procedure of Bligh 
& Dyer (1959) Can. J. Biochem. Physiol.29  After standing for 30 min at room temperature, 
125 mL chloroform and 50 mL of water were added to the tubes, which were then mixed by 
vortexing and centrifuged in a microfuge for 15 min. The upper, aqueous phase was transferred 
to a mini-column containing about 0.5 mL packed Dowex 1x8 resin (200-400 mesh), and the 
column run-through collected. The column was washed twice with 250 mL water and once with 
250 mL 50% aqueous ethanol, and the combined run-throughs were dried under a stream of 
air. In some experiments, the insoluble material remaining after chloroform/methanol/ water 
extraction was precipitated in 10% TCA after removal of the organic phase.  
B.5.5:       CHITOOLIGOSACCHARIDE DETECTION & VISUALIZATION 
COs were separated by thin layer chromatography (TLC) on silica gel 60 plates that had been 
pre-run in chloroform/methanol/water (65:25:4 v/v/v). Chromatograms were developed twice 
in butan-1-ol/ethanol/water (5:3:2 v/v/v), and radiolabeled material was detected by 
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phosphorimaging. Non-radioactive standards of GlcNAc, N,N’-diacetylchitobiose, and N,N’,N”-
triacetylchitotriose were detected by spraying with aniline-diphenylamine-phosphoric acid 
reagent.3 
B.5.6:       CHITOOLIGOSACCHARIDE EXTRACTION & PURIFICATION FOR MALDI ANALYSIS 
For bulk preparation of unlabeled COs, incubation mixtures (50 mL final volume) contained 
1.4 mM unlabeled UDP-GlcNAc and 0.25 mM cobalt acetate. The Dowex 1x8 run-throughs from 
seven parallel incubations were pooled, evaporated to dryness, and submitted to charcoal-
celite chromatography as follows. Mini-columns were prepared by loading a 5 mL disposable 
pipet tip with a slurry of equal amounts of activated charcoal and celite 545 in 5% aqueous 
ethanol, to give a column bed of 5 cm. CO samples were dissolved in 1 mL water and loaded 
onto the column, which was then washed with 10 mL 5% aqueous ethanol, and the eluate 
collected. The column was then eluted with 25 mL 30% aqueous ethanol, and five 5 mL 
fractions were collected. Analysis of the fractions by MALDI established that free GlcNAc and 
salt emerged predominantly in the 5% ethanol wash and in 30% ethanol fraction 1, whereas the 
COs were eluted predominantly in 30% ethanol, in fractions 2 and 3.36 
B.5.7:       ANALYSIS BY MASS SPECTROMETRY 
Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight (MALDI-TOF) mass spectrometry-
MALDI-TOF mass spectra were recorded on a Bruker-Daltonic Microflex LRF instrument (Bruker-
Daltonics, Billerica, MA) operating in reflectron mode. The system utilizes a pulsed nitrogen 
laser, emitting at 337 nm. Typically, 1000 - 2000 shots were acquired at 60 Hz frequency and 
78% laser power, with the laser attenuator offset at 16% for 30% range. The matrix was 
saturated 2,5-dihydrobenzoic acid in acetonitrile, and was pre-mixed with the samples (0.5 
mg.mL-1) prior to spotting onto a standard 96-position stainless steel target. Ion source 1 was 
set to 19.0 kV, and source 2 to 15.9 kV (83.7% of IS 1), with lens and reflector voltages of 9.79 
and 19.99 kV, respectively.  During the acquisition matrix ion suppression was used up to 200 
Da.  External calibration used Bruker Peptide Calibration Standard II mono with insulin.  The MS 
data were processed off-line using the Flex Analysis 3.0 software package (Bruker Daltonics). 
 106 
 
B.5.8:       SYNTHESIS OF GLCNAC ANALOGUES 
Preparation of 2-acylamido analogues of GlcNAc-Routine procedures and sources of reagents 
were as follows. Column chromatography was performed on silica gel 60 (70-230 mesh), 
reactions were monitored by TLC on Kieselgel 60 F254, and compounds were detected by 
examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents were 
removed under reduced pressure at < 40 oC. D-glucosamine*HCl, propionic anhydride, butyric 
anhydride, acetoxyacetyl chloride, anhydrous pyridine, anhydrous methanol, and inorganic 
compounds were purchased from Sigma-Aldrich and used as is. 1H- and 13C-n.m.r. spectra were 
recorded in D2O at 300 MHz or 75 MHz (Bruker Avance), respectively. 
 
GlcNPr and GlcNBu were prepared from D-glucosamine * HCl as described previously, and the 
analytical data for these compounds were practically the same as previously reported.30  For 
the preparation of GlcNGc, D-glucosamine * HCl (5.0 g, 23.2 mmol) was dissolved in cold water 
(25 mL) and NaHCO3 (5.8 g, 69.5 mmol) was added. The mixture was stirred vigorously in an ice 
bath and acetoxyacetyl chloride (3.0 mL, 27.8 mmol) was added dropwise. The resulting 
mixture was stirred for additional 2 h in the ice bath, then neutralized by dropwise addition of 
1M HCl.  The precipitate was filtered-off, washed with ice-cold water (10 mL) and dried. The 
crude product (~10 g) was dissolved in pyridine (50 mL) and acetic anhydride (25 mL) was 
added. The reaction mixture was stirred for 16 h at room temperature, then quenched by 
addition of methanol (~20 mL) and the volatiles were removed under reduced pressure. The 
residue was dissolved in CH2Cl2 (300 mL), and the organic phase was washed successively with 
water (200 mL), saturated aqueous NaHCO3 (200 mL), water (200 mL), 1M HCl (2 x 200 mL), and 
lastly, with water (2 x 200 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(methanol–dichloromethane gradient elution). The pure acetylated product (α-anomer, 2.3 g) 
was dissolved in methanol (5 mL) and 1M sodium methoxide in methanol (2.5 mL) were added 
giving a pH of 9, and the reaction mixture was stirred for 48 h at room temperature. The 
resulting mixture was neutralized with Dowex (H+), the resin was filtered-off and rinsed with 
methanol. The combined filtrate was concentrated in vacuo, and dried. The residue was 
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purified by column chromatography on silica gel (methanol–dichloromethane gradient elution) 
to afford GlcNGc (0.8 g) in 15% yield overall.  Selected analytical data for GlcNGc are: 13C-n.m.r. 
(α-anomer): δ, 53.6, 60.5, 60.8, 69.9, 70.7, 71.6, 90.8, 175.1 ppm; 13C-n.m.r. (β-anomer): δ, 
56.3, 60.7, 61.0, 69.8, 73.6, 75.9, 94.6, 175.6 ppm. The remaining analytical data were 




B.6        Figures 
 
 
CFFH.  ChemDraw15. Computer software. Perkin Elmer, n.d. Web. 
 
Figure   B.1:        β-(1,4)-polysaccharides: Cellulose & Chitin 
A. Cellulose & Chitin structures. Both cellulose and chitin are β-(1,4)-linked polysaccharides. Cellulose is composed 
of linked glucose (Glc) sugars while chitin is made of N-acetylglucosamine (GlcNAc) moieties.  The (1’) and (4’) ends 
of β-(1,4) polysaccharides are called the ‘reducing’ and ‘non-reducing’ ends of the polymer, respectively.  B. 
Reducing sugars.  The 1’ carbon at the end of the chain is a free anomeric carbon.  A C5 attack on the C1 (in the 






Artwork by CFFH 
Figure modeled from Cabib & Arroyo (2013)39 
 
Figure   B.2:        Saccharomyces cerevisiae Chitin Synthases 
Budding yeast. Saccharomyces cerevisiae has three chitin synthases: ScChs1, ScChs2, & ScChs3.  Each enzyme 
performs a distinct cellular function.  Chs1 is thought to repair chitinase damage to the cell wall septum after 
budding and daughter cell separation.23  Chs2 synthesizes chitin in the primary septum during cytokinesis.1, 24  Chs3 







Part A: PAB Orlean (2012) 
Part B: CFF Hebbard (2012-04) 
 
 
Figure   B.3:        Insoluble Chitin from Chs2-overexpressing Yeast (YO1535) 
A. CO synthesis. CHS2-overexpressing membranes (YO1535) or wild type Chs2-containing membranes with only 
the expression plasmid (YO1528) were resuspended in buffer and incubated with UDP-[14C]GlcNAc and UDP-
GlcNAc the presence of 32 mM GlcNAc. Incorporation of UDP-[14C]GlcNAc into insoluble chitin was quantified.  B.  
Substrate (UDP-*GlcNAc) usage.  YO1535 membranes were probed for activity using the typical Chs2 assay format.  
Supernatant liquid from the assays was passed through Dowex 1x8 resin to remove unreacted UDP-GlcNAc.  








Figure   B.4:        Time Course of Chs2 Aqueous Product   
Chs2-overexpressing membranes that had been resuspended in buffer were incubated with 125 nCi UDP-
[14C]GlcNAc for increasing time periods. Reactions were halted by incubating the samples at 100 oC for 5 minutes.  
Samples were centrifuged and the supernatant portion was isolated, passed through Dowex 1x8 resin, and 
submitted to separation by TLC on silica gel plates [butan-1-ol/ethanol/ water (5:3:2 v/v/v)].  Radiolabeled material 







Figure   B.5:        Chitinase destroys the ladder 
A. CO product degradation. Chs2-overexpressing membranes had been incubated for 15 minutes with substrate in 
a typical assay lacking free GlcNAc (as detailed in Materials & Methods). The resultant liquid was phase partitioned 
into aqueous-soluble, organic-soluble, and insoluble material.29  The aqueous fraction was cleaned from unreacted 
UDP-GlcNAc by passage through Dowex 1x8 resin.  All materials were dried in vacuo.  The organic and aqueous 
layers were resuspended in liquid and the Dowex-cleaned aqueous-soluble material was incubated with either 
chitinase buffer or with chitinase and chitinase buffer.  The organic sample and chitinase digestion products were 
separated by TLC on silica gel plates.  Plates were developed twice in butan-1-ol/ethanol/ water (5:3:2 v/v/v), after 
which radiolabeled material was detected by phosphorimaging as detailed in Experimental Procedures.  B. 
Chitinase digestion of products in the presence of free GlcNAc. Procedures were performed exactly as detailed 
above except that the 15-minute Chs2-incubation assay included 32 mM of GlcNAc.  All lanes are from the same 
experiment , day, and TLC run.  The lanes have been separated in the figure for purposes of rearranging the 
physical order in which the samples were submitted to the TLC plate for separation.  The full TLC plate can be seen 





Part A: CFFH (2012-04-12) 
Part B: CFF Hebbard (2012-06-20/28) 
Figure   B.6:        Stimulation of CO and Insoluble Chitin Synthesis by GlcNAc  
A. Substrate (UDP-*GlcNAc) usage.  Chs2-overexpression membranes were incubated with or without free GlcNAc 
in a time course.  Supernatant liquid from the assays was passed through Dowex 1x8 resin to remove unreacted 
UDP-GlcNAc.  Remaining UDP-[
14
C]GlcNAc radioactivity was measured from the Dowex resin by scintillation count.  
B & C. Quantification of COs and chitin & TLC. Chs2-overexpressing membranes were incubated with 125 nCi of 
UDP-[14C]GlcNAc and increasing amounts of unlabeled UDP-GlcNAc in the presence or absence of 32 mM GlcNAc. 
Reactions were halted, and reaction mixtures were phase partitioned and collected separately into aqueous-
soluble, organic-soluble, and insoluble material.29  Aqueous-soluble reaction products were isolated, passed 
through Dowex 1-X8 resin, and separated by TLC on silica gel plates that were developed twice in butan-1-
ol/ethanol/water (5:3:2 v/v/v), after which radiolabeled material was detected by phosphorimaging as detailed 
under Materials & Methods. Total amounts of COs from the material applied to the chromatogram (C) and total 
amounts of 10% TCA-insoluble chitin were determined and plotted against UDP-GlcNAc concentration (B).  The “- 
GlcNAc” time course in A is the same sample as that in Figure B.3, part B. 
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Part A: CFFH ran experiment (2012-06-20/28), PABO developed X-ray and Spray (2012-07)
Part B: Figure reproduced from Gyore et al. 2014
Structures: CFFH. ChemDraw15. Computer software. Perkin Elmer, n.d. Web.
Figure B.7: GlcNAc Analogues Stimulate Chitin Synthesis
A. Effects of GlcNAc2, GlcNAc3, glucose, and GlcN on CO formation. Chs2-overexpressing membranes that had
been resuspended in buffer were assayed for CO formation in the presence of 32 mM GlcNAc, GlcNAc2, GlcNAc3,
GlcN, GalNAc, ManNAc, or Glc under standard conditions. COs from the experiment were analyzed as described in
Materials & Methods. The same TLC silica plate from which radioactivity was recorded was subjected to
carbohydrate-specific chemical spray. B, Stimulation of CO formation synthesis by 2-acylamido-GlcNAc analogues.
Chs2-overexpressing membranes without glycerol were assayed for CO formation in the presence of GlcNAc2,
GlcNAc3, GlcNPr, GlcNBu, and GlcNGc, all at 32 mM. Chs2-overexpressing membranes were assayed for formation
of 10% TCA-insoluble chitin in the presence of the indicated concentrations of GlcNAc2, GlcNPr, GlcNBu, and
GlcNGc.
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Figure reproduced from Gyore et al. 2014
Figure B.8: Formation of COs in the Presence of GlcNPr, GlcNBu, and GlcNGc
Membranes from YO1535 Δcts1 cells overexpressing CHS2 were incubated with 1.4 mM unlabeled UDP-GlcNAc
and 32 mM GlcNPr, GlcNBu, or GlcNGc, and pooled CO fractions generated in seven replicate incubations were
chromatographed on activated charcoal-celite, concentrated, and submitted to MALDI. A, Material in m/z range of
disaccharides. B, Material in m/z range of trisaccharides. Calculated masses and molecular formulae for the
variously N-acylated CO disaccharide and trisaccharide sodium adduct [M + Na]+ ions observed by MALDI-TOF mass
spectrometry. The mass spectra are shown; structures are drawn assuming non-reducing end addition of GlcNAc.
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CFF Hebbard (2012-06-20/28)
Parts A & B: reproduced from Gyore et al. 2014
Part C: CFF Hebbard (2012-06-20/28)
Figure B.9: Comparison

















B.7        References 
1. Sburlati, A &  E Cabib. Chitin Synthetase-2, a Presumptive Participant in Septum 
Formation in Saccharomyces cerevisiae. J. Biol. Chem. 261, 5147-52 (1986). 
 
2. Orlean, P. 2 Chitin Synthases in Saccharomyces cerevisiae. J. Biol. Chem. 262, 5732-39 
(1987). 
 
3. Tanaka, T, S Fujiwara, S Nishikori, T Fukui, M Takagi &  T Imanaka. A Unique Chitinase 
with Dual Active Sites and Triple Substrate Binding Sites from the Hyperthermophilic 
Archaeon Pyrococcus Kodakaraensis Kod1. Applied and environmental microbiology 65, 
5338-44 (1999). 
 
4. Somerville, C. Cellulose Synthesis in Higher Plants. Annual review of cell and 
developmental biology 22, 53-78 (2006). 
 
5. Weigel, PH &  PL DeAngelis. Hyaluronan Synthases: A Decade-Plus of Novel 
Glycosyltransferases. J. Biol. Chem. 282, 36777-81 (2007). 
 
6. Cantarel, BL, PM Coutinho, C Rancurel, T Bernard, V Lombard &  B Henrissat. The 
Carbohydrate-Active Enzymes Database (Cazy): An Expert Resource for Glycogenomics. 
Nucleic Acids Res 37, D233-8 (2009). 
 
7. Merzendorfer, H. The Cellular Basis of Chitin Synthesis in Fungi and Insects: Common 
Principles and Differences. Eur J Cell Biol 90, 759-69 (2011). 
 
8. Orlean, P. Architecture and Biosynthesis of the Saccharomyces cerevisiae Cell Wall. 
Genetics 192, 775-818 (2012). 
 
9. Carpita, NC. Update on Mechanisms of Plant Cell Wall Biosynthesis: How Plants Make 
Cellulose and Other (1->4)-Beta-D-Glycans. Plant Physiol. 155, 171-84 (2011). 
 
10. Morgan, JL, J Strumillo &  J Zimmer. Crystallographic Snapshot of Cellulose Synthesis and 
Membrane Translocation. Nature 493, 181-6 (2013). 
 
11. Romling, U &  MY Galperin. Bacterial Cellulose Biosynthesis: Diversity of Operons, 
Subunits, Products, and Functions. Trends in microbiology,  (2015). 
 
12. Slabaugh, E, JK Davis, CH Haigler, YG Yingling &  J Zimmer. Cellulose Synthases: New 




13. Keller, FA &  E Cabib. Chitin and Yeast Budding. Properties of Chitin Synthetase from 
Saccharomyces carlsbergensis. J. Biol. Chem. 246, 160-6 (1971). 
 
14. Fahnrich, M &  J Ahlers. Improved Assay and Mechanism of the Reaction Catalyzed by 
the Chitin Synthase from Saccharomyces cerevisiae. Eur J Biochem 121, 113-8 (1981). 
 
15. Nagahashi, S, M Sudoh, N Ono, R Sawada, E Yamaguchi, Y Uchida, T Mio, M Takagi, M 
Arisawa &  H Yamada-Okabe. Characterization of Chitin Synthase 2 of Saccharomyces 
cerevisiae. Implication of Two Highly Conserved Domains as Possible Catalytic Sites. J. 
Biol. Chem. 270, 13961-7 (1995). 
 
16. Horsch, M, C Mayer &  DM Rast. Stereochemical Requirements of Chitin Synthase for 
Ligand Binding at the Allosteric Site for N-Acetylglucosamine. Eur J Biochem 237, 476-82 
(1996). 
 
17. Glaser, L &  DH Brown. The Synthesis of Chitin in Cell-Free Extracts of Neurospora 
crassa. J. Biol. Chem. 228, 729-42 (1957). 
 
18. Porter, CA &  EG Jaworski. The Synthesis of Chitin by Particulate Preparations of 
Allomyces macrogynus. Biochemistry 5, 1149-54 (1966). 
 
19. Camargo, EP, CP Dietrich, D Sonneborn &  JL Strominger. Biosynthesis of Chitin in Spores 
and Growing Cells of Blastocladiella emersonii. J. Biol. Chem. 242, 3121-8 (1967). 
 
20. McMurrough, I &  S Bartnicki-Garcia. Properties of a Particulate Chitin Synthetase from 
Mucor rouxii. J. Biol. Chem. 246, 4008-16 (1971). 
 
21. Oh, Y, KJ Chang, P Orlean, C Wloka, R Deshaies &  E Bi. Mitotic Exit Kinase Dbf2 Directly 
Phosphorylates Chitin Synthase Chs2 to Regulate Cytokinesis in Budding Yeast. Mol Biol 
Cell 23, 2445-56 (2012). 
 
22. Valdivieso, MH, PC Mol, JA Shaw, E Cabib &  A Duran. Cal1, a Gene Required for Activity 
of Chitin Synthase 3 in Saccharomyces cerevisiae. J Cell Biol 114, 101-9 (1991). 
 
23. Cabib, E, A Sburlati, B Bowers &  SJ Silverman. Chitin Synthase 1, an Auxiliary Enzyme for 
Chitin Synthesis in Saccharomyces cerevisiae. J Cell Biol 108, 1665-72 (1989). 
 
24. Shaw, JA, PC Mol, B Bowers, SJ Silverman, MH Valdivieso, A Duran &  E Cabib. The 
Function of Chitin Synthases 2 and 3 in the Saccharomyces cerevisiae Cell Cycle. J Cell 




25. Kang, JS, YD Yoon, MH Han, SB Han, K Lee, SK Park &  HM Kim. Equol Inhibits Nitric 
Oxide Production and Inducible Nitric Oxide Synthase Gene Expression through Down-
Regulating the Activation of Akt. Int Immunopharmacol 7, 491-9 (2007). 
 
26. Kang, MS, N Elango, E Mattia, J Au-Young, PW Robbins &  E Cabib. Isolation of Chitin 
Synthetase from Saccharomyces cerevisiae. Purification of an Enzyme by Entrapment in 
the Reaction Product. J. Biol. Chem. 259, 14966-72 (1984). 
 
27. Yabe, T, T Yamada-Okabe, T Nakajima, M Sudoh, M Arisawa &  H Yamada-Okabe. 
Mutational Analysis of Chitin Synthase 2 of Saccharomyces cerevisiae. Identification of 
Additional Amino Acid Residues Involved in Its Catalytic Activity. Eur J Biochem 258, 941-
7 (1998). 
 
28. Kamst, E, J Bakkers, NE Quaedvlieg, J Pilling, JW Kijne, BJ Lugtenberg &  HP Spaink. Chitin 
Oligosaccharide Synthesis by Rhizobia and Zebrafish Embryos Starts by Glycosyl Transfer 
to O4 of the Reducing-Terminal Residue. Biochemistry 38, 4045-52 (1999). 
 
29. Bligh, EG &  WJ Dyer. A Rapid Method of Total Lipid Extraction and Purification. 
Canadian journal of biochemistry and physiology 37, 911-7 (1959). 
 
30. Kristova, V, L Martinkova, L Husakova, M Kuzma, J Rauvolfova, D Kavan, P Pompach, K 
Bezouska &  V Kren. A Chemoenzymatic Route to Mannosamine Derivatives Bearing 
Different N-Acyl Groups. Journal of Biotechnology 115, 157-66 (2005). 
 
31. Lopez-Romero, E &  J Ruiz-Herrara. Synthesis of Chitin by Particulate Preparations from 
Aspergillus flavus. Antonie Van Leeuwenhoek 42, 261-76 (1976). 
 
32. Levengood, MR, RA Splain &  LL Kiessling. Monitoring Processivity and Length Control of 
a Carbohydrate Polymerase. J Am Chem Soc 133, 12758-66 (2011). 
 
33. Cabib, E. The Synthesis and Degradation of Chitin. Advances in enzymology and related 
areas of molecular biology 59, 59-101 (1987). 
 
34. Carrano, L, P Tavecchia, F Sponga &  F Spreafico. Dansyl N-Acetyl Glucosamine as a 
Precursor of Fluorescent Chitin: A Method to Detect Fungal Cell Wall Inhibitors. The 
Journal of antibiotics 50, 177-9 (1997). 
 
35. Baudin, A, O Ozier-Kalogeropoulos, A Denouel, F Lacroute &  C Cullin. A Simple and 
Efficient Method for Direct Gene Deletion in Saccharomyces cerevisiae. Nucleic Acids 
Res 21, 3329-30 (1993). 
 
36. Redmond, JW &  NH Packer. The Use of Solid-Phase Extraction with Graphitised Carbon 




37. Jourdian, GW &  S Roseman. Sialic Acids .2. Preparation of N-Glycolylhexosamines, N-
Glycolylhexosamine 6-Phosphates, Glycolyl Coenzyme A, and Glycolyl Glutathione. J. 
Biol. Chem. 237, 2442-& (1962). 
 
38. Lubineau, A, C Auge, C Gautheron-Le Narvor &  JC Ginet. Combined Chemical and 
Enzymatic Synthesis of the Sialylated Non Reducing Terminal Sequence of Gm1b 
Glycolylated Ganglioside, a Potential Human Tumor Marker. Bioorg Med Chem 2, 669-74 
(1994). 
 
39. Cabib, E &  J Arroyo. How Carbohydrates Sculpt Cells: Chemical Control of 
Morphogenesis in the Yeast Cell Wall. Nat Rev Microbiol 11, 648-55 (2013). 
 
 
 
 
 
 
 
